BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, Dewoody KL, Schaible TF, Rutgeerts PJ. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease. N Engl J Med 1997;337:1029-36. [DOI: 10.1056/nejm199710093371502] [Cited by in Crossref: 2234] [Cited by in F6Publishing: 542] [Article Influence: 89.4] [Reference Citation Analysis]
Number Citing Articles
1 Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M, Lobo A. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2016;34:1241-53. [PMID: 27480631 DOI: 10.1007/s40273-016-0436-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
2 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
3 Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci. 2015;60:951-956. [PMID: 25326115 DOI: 10.1007/s10620-014-3392-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
4 Edelblum KL, Goettel JA, Koyama T, McElroy SJ, Yan F, Polk DB. TNFR1 promotes tumor necrosis factor-mediated mouse colon epithelial cell survival through RAF activation of NF-kappaB. J Biol Chem 2008;283:29485-94. [PMID: 18713739 DOI: 10.1074/jbc.M801269200] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
5 Oprins JC, van der Burg C, Meijer HP, Munnik T, Groot JA. Tumour necrosis factor alpha potentiates ion secretion induced by histamine in a human intestinal epithelial cell line and in mouse colon: involvement of the phospholipase D pathway. Gut. 2002;50:314-321. [PMID: 11839707 DOI: 10.1136/gut.50.3.314] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vereecke L, Sze M, Mc Guire C, Rogiers B, Chu Y, Schmidt-Supprian M, Pasparakis M, Beyaert R, van Loo G. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med. 2010;207:1513-1523. [PMID: 20530205 DOI: 10.1084/jem] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009;23:348-52. [PMID: 19440565 DOI: 10.1155/2009/180840] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
8 Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015;42:504-514. [PMID: 26119226 DOI: 10.1111/apt.13291] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
9 Ye D, Guo S, Al-Sadi R, Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology. 2011;141:1323-1333. [PMID: 21763238 DOI: 10.1053/j.gastro.2011.07.005] [Cited by in Crossref: 176] [Cited by in F6Publishing: 170] [Article Influence: 16.0] [Reference Citation Analysis]
10 Donath MY, Hess C, Palmer E. What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia 2014;57:653-5. [PMID: 24389751 DOI: 10.1007/s00125-013-3153-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
11 Shim HH, Chan PW, Chuah SW, Schwender BJ, Kong SC, Ling KL. A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2018;2:223-34. [PMID: 30483594 DOI: 10.1002/jgh3.12065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
12 Iliopoulou L, Kollias G. Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment. Mucosal Immunol 2021. [PMID: 34316007 DOI: 10.1038/s41385-021-00433-3] [Reference Citation Analysis]
13 Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med. 2015;21:730-738. [PMID: 26121193 DOI: 10.1038/nm.3897] [Cited by in Crossref: 132] [Cited by in F6Publishing: 117] [Article Influence: 18.9] [Reference Citation Analysis]
14 Zundler S, Becker E, Weidinger C, Siegmund B. Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects. Front Immunol. 2017;8:891. [PMID: 28804488 DOI: 10.3389/fimmu.2017.00891] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
15 Bregenholt S, Brimnes J, Nissen MH, Claesson MH. In vitro activated CD4+ T cells from interferon-gamma (IFN-gamma)-deficient mice induce intestinal inflammation in immunodeficient hosts. Clin Exp Immunol 1999;118:228-34. [PMID: 10540183 DOI: 10.1046/j.1365-2249.1999.01058.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
16 Khanna R, Zou G, Feagan BG. Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. Inflamm Bowel Dis 2018;24:2155-64. [PMID: 29788218 DOI: 10.1093/ibd/izy117] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Balding J, Livingstone WJ, Conroy J, Mynett-Johnson L, Weir DG, Mahmud N, Smith OP. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm. 2004;13:181-187. [PMID: 15223609 DOI: 10.1080/09511920410001713529] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 2.8] [Reference Citation Analysis]
18 Hampe J, Shaw SH, Saiz R, Leysens N, Lantermann A, Mascheretti S, Lynch NJ, MacPherson AJ, Bridger S, van Deventer S. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet. 1999;65:1647-1655. [PMID: 10577918 DOI: 10.1086/302677] [Cited by in Crossref: 152] [Cited by in F6Publishing: 154] [Article Influence: 6.9] [Reference Citation Analysis]
19 de Vries HS, van Oijen MG, Driessen RJ, de Jong EM, Creemers MC, Kievit W, de Jong DJ. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011;71:7-19. [PMID: 21143496 DOI: 10.1111/j.1365-2125.2010.03760.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
20 Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs. 2001;61:777-787. [PMID: 11398909 DOI: 10.2165/00003495-200161060-00006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
21 Cadwell K, Patel KK, Maloney NS, Liu TC, Ng AC, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell. 2010;141:1135-1145. [PMID: 20602997 DOI: 10.1016/j.cell.2010.05.009] [Cited by in Crossref: 642] [Cited by in F6Publishing: 590] [Article Influence: 53.5] [Reference Citation Analysis]
22 Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139. [PMID: 20145610 DOI: 10.1038/ajg.2010.9] [Cited by in Crossref: 356] [Cited by in F6Publishing: 332] [Article Influence: 29.7] [Reference Citation Analysis]
23 Marini JC, Sendecki J, Cornillie F, Popp JW Jr, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®. AAPS J 2017;19:161-71. [PMID: 27600137 DOI: 10.1208/s12248-016-9981-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
24 Lloyd K, Papoutsopoulou S, Smith E, Stegmaier P, Bergey F, Morris L, Kittner M, England H, Spiller D, White MHR, Duckworth CA, Campbell BJ, Poroikov V, Martins Dos Santos VAP, Kel A, Muller W, Pritchard DM, Probert C, Burkitt MD; SysmedIBD Consortium. Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease. Dis Model Mech 2020;13:dmm044040. [PMID: 32958515 DOI: 10.1242/dmm.044040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Triantafillidis JK, Papalois AE, Parasi A, Anagnostakis E, Burnazos S, Gikas A, Merikas EG, Douzinas E, Karagianni M, Sotiriou H. Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. World J Gastroenterol 2005; 11(43): 6843-6847 [PMID: 16425394 DOI: 10.3748/wjg.v11.i43.6843] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
26 Park MY, Yoon YS, Lee JL, Park SH, Ye BD, Yang SK, Yu CS. Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn's disease: a retrospective observational study. Stem Cell Res Ther 2021;12:401. [PMID: 34256838 DOI: 10.1186/s13287-021-02484-6] [Reference Citation Analysis]
27 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
28 Kobayashi M, Kweon MN, Kuwata H, Schreiber RD, Kiyono H, Takeda K, Akira S. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 2003;111:1297-308. [PMID: 12727921 DOI: 10.1172/JCI17085] [Cited by in Crossref: 163] [Cited by in F6Publishing: 88] [Article Influence: 8.6] [Reference Citation Analysis]
29 Sakisaka H, Takedatsu H, Mitsuyama K, Mochizuki S, Sakurai K, Sakisaka S, Hirai F. Topical Therapy with Antisense Tumor Necrosis Factor Alpha Using Novel β-Glucan-Based Drug Delivery System Ameliorates Intestinal Inflammation. Int J Mol Sci 2020;21:E683. [PMID: 31968666 DOI: 10.3390/ijms21020683] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
30 Dobsch P, Michels B, Müller-Schilling M, Kandulski A. [Therapeutic regimens using monoclonal antibodies in gastroenterology]. Internist (Berl) 2019;60:1043-58. [PMID: 31501913 DOI: 10.1007/s00108-019-00682-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59 Suppl 1:i21-7. [PMID: 11053081 DOI: 10.1136/ard.59.suppl_1.i21] [Cited by in Crossref: 128] [Cited by in F6Publishing: 128] [Article Influence: 5.8] [Reference Citation Analysis]
32 Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:998-1009. [PMID: 26835982 DOI: 10.1097/MIB.0000000000000661] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
33 Na SY, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut Liver. 2019;13:604-616. [PMID: 31195433 DOI: 10.5009/gnl19019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
34 Blumberg RS. Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis. 2009;27:455-464. [PMID: 19897960 DOI: 10.1159/000235851] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
35 Rui M, Fei Z, Wang Y, Shi F, Meng R, Shang Y, Ma A, Li H. Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis. Front Med (Lausanne) 2021;8:679258. [PMID: 34540859 DOI: 10.3389/fmed.2021.679258] [Reference Citation Analysis]
36 Schreiber S, Hampe J, Eickhoff H, Lehrach H. Functional genomics in gastroenterology. Gut 2000;47:601-7. [PMID: 11034570 DOI: 10.1136/gut.47.5.601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
37 Roulis M, Armaka M, Manoloukos M, Apostolaki M, Kollias G. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci U S A 2011;108:5396-401. [PMID: 21402942 DOI: 10.1073/pnas.1007811108] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 7.6] [Reference Citation Analysis]
38 Gonçalves NS, Ghaem-Maghami M, Monteleone G, Frankel G, Dougan G, Lewis DJ, Simmons CP, MacDonald TT. Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect Immun 2001;69:6651-9. [PMID: 11598034 DOI: 10.1128/IAI.69.11.6651-6659.2001] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
39 Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazalé T, Raupach B, Eckert J, Schumann RR, Enders C, Sonnenborn U. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun. 2005;73:1452-1465. [PMID: 15731043 DOI: 10.1128/IAI.73.3.1452-1465] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Frasca JD, Cheifetz AS. The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth. Ann Transl Med 2019;7:S388. [PMID: 32016106 DOI: 10.21037/atm.2019.12.86] [Reference Citation Analysis]
41 Zhong H, Bussel J, Yazdanbakhsh K. In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia. Br J Haematol 2015;168:274-83. [PMID: 25252160 DOI: 10.1111/bjh.13126] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
42 Lew D, Yoon SM, Yan X, Robbins L, Haritunians T, Liu Z, Li D, McGovern DP. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients. World J Gastroenterol 2017; 23(40): 7265-7273 [PMID: 29142473 DOI: 10.3748/wjg.v23.i40.7265] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
43 Du W, Erden O, Pang Q. TNF-α signaling in Fanconi anemia. Blood Cells Mol Dis 2014;52:2-11. [PMID: 23890415 DOI: 10.1016/j.bcmd.2013.06.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
44 Sturm A, Fiocchi C. Life and death in the gut: more killing, less Crohn's. Gut 2002;50:148-9. [PMID: 11788550 DOI: 10.1136/gut.50.2.148] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
45 McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn’s disease in adults. Drugs. 2002;62:2263-2282. [PMID: 12381231 DOI: 10.2165/00003495-200262150-00015] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
46 Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 84] [Article Influence: 11.3] [Reference Citation Analysis]
47 Jijon HB, Buret A, Hirota CL, Hollenberg MD, Beck PL. The EGF receptor and HER2 participate in TNF-α-dependent MAPK activation and IL-8 secretion in intestinal epithelial cells. Mediators Inflamm 2012;2012:207398. [PMID: 22988345 DOI: 10.1155/2012/207398] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
48 Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci 2013;9:765-79. [PMID: 24273556 DOI: 10.5114/aoms.2013.38670] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
49 Scott FI, Lichtenstein GR. Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review. Curr Treat Options Gastroenterol 2016;14:91-102. [PMID: 26847358 DOI: 10.1007/s11938-016-0085-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
50 Zareie M, Singh PK, Irvine EJ, Sherman PM, McKay DM, Perdue MH. Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn’s disease. Am J Pathol. 2001;158:1101-1109. [PMID: 11238058 DOI: 10.1016/s0002-9440(10)64057-6] [Cited by in Crossref: 67] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
51 Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, Sakuraba A, Fukushima T, Uede T, Hibi T. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005;54:1254-62. [PMID: 16099792 DOI: 10.1136/gut.2004.048298] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 5.4] [Reference Citation Analysis]
52 Baumgart DC, Metzke D, Guckelberger O, Pascher A, Grötzinger C, Przesdzing I, Dörffel Y, Schmitz J, Thomas S. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clin Exp Immunol 2011;166:46-54. [PMID: 21762123 DOI: 10.1111/j.1365-2249.2011.04439.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
53 Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY. Mucinous carcinoma in Crohn’s disease originating in a fistulous tract. World J Gastrointest Oncol 2010; 2(7): 307-310 [PMID: 21160662 DOI: 10.4251/wjgo.v2.i7.307] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
54 Goodman WA, Omenetti S, Date D, Di Martino L, De Salvo C, Kim GD, Chowdhry S, Bamias G, Cominelli F, Pizarro TT, Mahabeleshwar GH. KLF6 contributes to myeloid cell plasticity in the pathogenesis of intestinal inflammation. Mucosal Immunol 2016;9:1250-62. [PMID: 26838049 DOI: 10.1038/mi.2016.1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
55 Hoffman IE, Demetter P, Peeters M, De Vos M, Mielants H, Veys EM, De Keyser F. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003;62:455-9. [PMID: 12695160 DOI: 10.1136/ard.62.5.455] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
56 Rossi RE, Parisi I, Despott EJ, Burroughs AK, O'Beirne J, Conte D, Hamilton MI, Murray CD. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014; 20(46): 17352-17359 [PMID: 25516646 DOI: 10.3748/wjg.v20.i46.17352] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
57 Tanida S, Ozeki K, Mizoshita T, Tsukamoto H, Katano T, Kataoka H, Kamiya T, Joh T. Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol 2015;8:131-40. [PMID: 25914555 DOI: 10.2147/CEG.S61868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
58 Pascual V, Dieli-Crimi R, López-Palacios N, Bodas A, Medrano LM, Núñez C. Inflammatory bowel disease and celiac disease: Overlaps and differences. World J Gastroenterol 2014; 20(17): 4846-4856 [PMID: 24803796 DOI: 10.3748/wjg.v20.i17.4846] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
59 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
60 Boismenu R, Chen Y, Chou K, El-Sheikh A, Buelow R. Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Ann Rheum Dis 2002;61 Suppl 2:ii19-24. [PMID: 12379615 DOI: 10.1136/ard.61.suppl_2.ii19] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
61 Minar P, Saeed SA, Afreen M, Kim MO, Denson LA. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2016;62:715-22. [PMID: 26551317 DOI: 10.1097/MPG.0000000000001029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
62 Deora A, Hegde S, Lee J, Choi CH, Chang Q, Lee C, Eaton L, Tang H, Wang D, Lee D, Michalak M, Tomlinson M, Tao Q, Gaur N, Harvey B, McLoughlin S, Labkovsky B, Ghayur T. Transmembrane TNF-dependent uptake of anti-TNF antibodies. MAbs 2017;9:680-95. [PMID: 28323513 DOI: 10.1080/19420862.2017.1304869] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
63 Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007;10:178-184. [PMID: 17547856 DOI: 10.1007/s11938-007-0011-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
64 Takeshima F, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Machida H, Matsushima K, Minami H, Akazawa Y, Yamaguchi N, Ohnita K, Isomoto H, Ueno M, Nakao K. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. BMC Gastroenterol 2016;16:82. [PMID: 27472988 DOI: 10.1186/s12876-016-0501-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
65 Söderholm JD, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 2004;53:1817-24. [PMID: 15542521 DOI: 10.1136/gut.2004.041426] [Cited by in Crossref: 100] [Cited by in F6Publishing: 103] [Article Influence: 5.6] [Reference Citation Analysis]
66 Dave M, Papadakis KA, Faubion WA. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am. 2014;43:405-424. [PMID: 25110250 DOI: 10.1016/j.gtc.2014.05.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
67 Taylor PC. Antibodies for inflammatory disease : cytokines. Methods Mol Med 2000;40:115-39. [PMID: 21337087 DOI: 10.1385/1-59259-076-4:115] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
68 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 15.0] [Reference Citation Analysis]
69 Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl) 2016;6:7-32. [PMID: 29387591 DOI: 10.2147/PTT.S64950] [Cited by in Crossref: 22] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
70 Lu Y, Li L, Zhang JW, Zhong XQ, Wei JA, Han L. Total polysaccharides of the Sijunzi decoction attenuate tumor necrosis factor-α-induced damage to the barrier function of a Caco-2 cell monolayer via the nuclear factor-κB-myosin light chain kinase-myosin light chain pathway. World J Gastroenterol 2018; 24(26): 2867-2877 [PMID: 30018481 DOI: 10.3748/wjg.v24.i26.2867] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
71 Oh EH, Oh K, Han M, Seo H, Chang K, Lee SH, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors. PLoS One 2017;12:e0177479. [PMID: 28542298 DOI: 10.1371/journal.pone.0177479] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
72 Sales-Campos H, Basso PJ, Alves VB, Fonseca MT, Bonfá G, Nardini V, Cardoso CR. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res. 2015;48:96-107. [PMID: 25466162 DOI: 10.1590/1414-431x20143774] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
73 Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063. [PMID: 22613901 DOI: 10.1038/ajg.2012.89] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 13.7] [Reference Citation Analysis]
74 Markovics A, Rosenthal KS, Mikecz K, Carambula RE, Ciemielewski JC, Zimmerman DH. Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models. Biomedicines 2022;10:44. [DOI: 10.3390/biomedicines10010044] [Reference Citation Analysis]
75 Vereecke L, Sze M, Mc Guire C, Rogiers B, Chu Y, Schmidt-Supprian M, Pasparakis M, Beyaert R, van Loo G. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med. 2010;207:1513-1523. [PMID: 20530205 DOI: 10.1084/jem.20092474] [Cited by in Crossref: 217] [Cited by in F6Publishing: 211] [Article Influence: 18.1] [Reference Citation Analysis]
76 Bamias G, Clark DJ, Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets 2013;14:1490-500. [PMID: 23621509 DOI: 10.2174/13894501113149990158] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
77 Cohavy O, Shih DQ, Doherty TM, Ware CF, Targan SR. CD161 DEFINES EFFECTOR T CELLS THAT EXPRESS LIGHT AND RESPOND TO TL1A-DR3 SIGNALING. Eur J Microbiol Immunol (Bp) 2011;1:70-9. [PMID: 22348196 DOI: 10.1556/EuJMI.1.2011.1.9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
78 Merger M, Viney JL, Borojevic R, Steele-Norwood D, Zhou P, Clark DA, Riddell R, Maric R, Podack ER, Croitoru K. Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut. 2002;51:155-163. [PMID: 12117872 DOI: 10.1136/gut.51.2.155] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 3.6] [Reference Citation Analysis]
79 Wang Q, Yang K, Han B, Sheng B, Yin J, Pu A, Li L, Sun L, Yu M, Qiu Y, Xiao W, Yang H. Aryl hydrocarbon receptor inhibits inflammation in DSS‑induced colitis via the MK2/p‑MK2/TTP pathway. Int J Mol Med 2018;41:868-76. [PMID: 29207040 DOI: 10.3892/ijmm.2017.3262] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
80 Asada T, Nakayama G, Tanaka C, Kobayashi D, Ezaka K, Hattori N, Kanda M, Yamada S, Koike M, Kodera Y. Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study). Surg Today 2018;48:609-17. [PMID: 29476258 DOI: 10.1007/s00595-018-1634-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
81 Sasaki F, Koga T, Saeki K, Okuno T, Kazuno S, Fujimura T, Ohkawa Y, Yokomizo T. Biochemical and immunological characterization of a novel monoclonal antibody against mouse leukotriene B4 receptor 1. PLoS One 2017;12:e0185133. [PMID: 28922396 DOI: 10.1371/journal.pone.0185133] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
82 D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-35. [PMID: 25281416 DOI: 10.1136/gutjnl-2014-307118] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
83 Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ 2013;14:853-61. [PMID: 22975794 DOI: 10.1007/s10198-012-0430-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
84 Dhanda AD, Lee RW, Collins PL, McCune CA. Molecular targets in the treatment of alcoholic hepatitis. World J Gastroenterol 2012; 18(39): 5504-5513 [PMID: 23112542 DOI: 10.3748/wjg.v18.i39.5504] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
85 Diaz-Granados N, Howe K, Lu J, McKay DM. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 2000;156:2169-77. [PMID: 10854237 DOI: 10.1016/S0002-9440(10)65087-0] [Cited by in Crossref: 94] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
86 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
87 Weizman AV, Nguyen GC. Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. World J Gastroenterol 2013; 19(38): 6375-6382 [PMID: 24151356 DOI: 10.3748/wjg.v19.i38.6375] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
88 Javey G, Schwartz SG, Flynn HW Jr. Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res 2012;2012:548732. [PMID: 22474425 DOI: 10.1155/2012/548732] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
89 Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg 2016; 8(5): 363-370 [PMID: 27231514 DOI: 10.4240/wjgs.v8.i5.363] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
90 Büning C, Lochs H. Conventional therapy for Crohn’s disease. World J Gastroenterol 2006; 12(30): 4794-4806 [PMID: 16937460 DOI: 10.3748/wjg.v12.i30.4794] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
91 Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010;38:82-9. [PMID: 19565360 DOI: 10.1007/s12016-009-8140-3] [Cited by in Crossref: 125] [Cited by in F6Publishing: 101] [Article Influence: 10.4] [Reference Citation Analysis]
92 Kaya B, Melhem H, Niess JH. GPR35 in Intestinal Diseases: From Risk Gene to Function. Front Immunol 2021;12:717392. [PMID: 34790192 DOI: 10.3389/fimmu.2021.717392] [Reference Citation Analysis]
93 Ye D, Ma TY. Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med. 2008;12:1331-1346. [PMID: 18363837 DOI: 10.1111/j.1582-4934.2008.00302.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
94 Hubbard VM, Cadwell K. Viruses, autophagy genes, and Crohn's disease. Viruses 2011;3:1281-311. [PMID: 21994779 DOI: 10.3390/v3071281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
95 McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB, Nold MF, Nold-Petry C, Bufler P, Dinarello CA. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA. 2011;108:16711-16716. [PMID: 21873195 DOI: 10.1073/pnas.1111982108] [Cited by in Crossref: 221] [Cited by in F6Publishing: 222] [Article Influence: 20.1] [Reference Citation Analysis]
96 Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853. [PMID: 15138212 DOI: 10.1136/gut.2003.018515] [Cited by in Crossref: 206] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
97 Assi K, Pillai R, Gómez-Muñoz A, Owen D, Salh B. The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis. Immunology 2006;118:112-21. [PMID: 16630028 DOI: 10.1111/j.1365-2567.2006.02349.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 5.0] [Reference Citation Analysis]
98 Nakai M, Sudo K, Yamada Y, Kojima Y, Kato T, Saito K, Moriwaki H, Seishima M. The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. Dig Dis Sci 2005;50:1669-76. [PMID: 16133967 DOI: 10.1007/s10620-005-2913-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
99 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
100 Vatay A, Bene L, Kovács A, Prohászka Z, Szalai C, Romics L, Fekete B, Karádi I, Füst G. Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Immunogenetics. 2003;55:247-252. [PMID: 12811429 DOI: 10.1007/s00251-003-0575-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 2.4] [Reference Citation Analysis]
101 Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:i16-35. [PMID: 16481629 DOI: 10.1136/gut.2005.081950b] [Cited by in Crossref: 423] [Cited by in F6Publishing: 365] [Article Influence: 26.4] [Reference Citation Analysis]
102 Kelly JC, Lungchukiet P, Macleod RJ. Extracellular Calcium-Sensing Receptor Inhibition of Intestinal EpithelialTNF Signaling Requires CaSR-Mediated Wnt5a/Ror2 Interaction. Front Physiol. 2011;2:17. [PMID: 21603229 DOI: 10.3389/fphys.2011.00017] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
103 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
104 Baran B, Karaca C. Practical medical management of Crohn's disease. ISRN Gastroenterol 2013;2013:208073. [PMID: 24307950 DOI: 10.1155/2013/208073] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
105 Landek-Salgado MA, Rose NR, Caturegli P. Placenta suppresses experimental autoimmune hypophysitis through soluble TNF receptor 1. J Autoimmun 2012;38:J88-96. [PMID: 21788115 DOI: 10.1016/j.jaut.2011.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
106 McKay DM, Baird AW. Cytokine regulation of epithelial permeability and ion transport. Gut 1999;44:283-9. [PMID: 9895392 DOI: 10.1136/gut.44.2.283] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 4.9] [Reference Citation Analysis]
107 Quinn DN, Pfeil SA. Gastroenterology. Clinics in Podiatric Medicine and Surgery 2002;19:23-42. [DOI: 10.1016/s0891-8422(03)00079-x] [Reference Citation Analysis]
108 Qian BF, Tonkonogy SL, Balfour Sartor R. Luminal bacterial antigen-specific CD4+ T-cell responses in HLA-B27 transgenic rats with chronic colitis are mediated by both major histocompatibility class II and HLA-B27 molecules. Immunology 2006;117:319-28. [PMID: 16476051 DOI: 10.1111/j.1365-2567.2005.02303.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
109 Vincenzi F, Bizzarri B, Ghiselli A, de’ Angelis N, Fornaroli F, de’ Angelis GL. Cystic fibrosis and Crohn’s disease: Successful treatment and long term remission with infliximab. World J Gastroenterol 2010; 16(15): 1924-1927 [PMID: 20397273 DOI: 10.3748/wjg.v16.i15.1924] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
110 Hadji H, Bouchemal K. Advances in the Treatment of Inflammatory Bowel Disease: Focus on Polysaccharide Nanoparticulate Drug Delivery Systems. Advanced Drug Delivery Reviews 2022. [DOI: 10.1016/j.addr.2021.114101] [Reference Citation Analysis]
111 Parhar K, Ray A, Steinbrecher U, Nelson C, Salh B. The p38 mitogen-activated protein kinase regulates interleukin-1beta-induced IL-8 expression via an effect on the IL-8 promoter in intestinal epithelial cells. Immunology 2003;108:502-12. [PMID: 12667212 DOI: 10.1046/j.1365-2567.2003.01603.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 2.6] [Reference Citation Analysis]
112 Winfield RD, Delano MJ, Pande K, Scumpia PO, Laface D, Moldawer LL. Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem. JPEN J Parenter Enteral Nutr 2008;32:651-5. [PMID: 18974247 DOI: 10.1177/0148607108325075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
113 Löfberg R. Treatment of fistulas in Crohn's disease with infliximab. Gut 1999;45:642-3. [PMID: 10517896 DOI: 10.1136/gut.45.5.642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
114 Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015;8:143-59. [PMID: 25949527 DOI: 10.1177/1756283X15576462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
115 Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, De Vos M, Van den Bosch F, Elewaut D. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 2020;16:415-33. [PMID: 32661321 DOI: 10.1038/s41584-020-0454-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
116 Ohkawara T, Koyama Y, Onodera S, Takeda H, Kato M, Asaka M, Nishihira J. DNA vaccination targeting macrophage migration inhibitory factor prevents murine experimental colitis. Clin Exp Immunol 2011;163:113-22. [PMID: 21062270 DOI: 10.1111/j.1365-2249.2010.04277.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
117 Louis E, Belaiche J, Reenaers C. Are we giving biologics too much time? When should we stop treatment? World J Gastroenterol 2008; 14(36): 5528-5531 [PMID: 18810771 DOI: 10.3748/wjg.14.5528] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
118 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
119 Hodgson R, Walton M, Biswas M, Mebrahtu T, Woolacott N. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2018;36:387-98. [PMID: 29192397 DOI: 10.1007/s40273-017-0593-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
120 Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis. 2005;20:1-8. [PMID: 15459771 DOI: 10.1007/s00384-004-0634-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
121 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349-1362. [PMID: 24749763 DOI: 10.1111/apt.12749] [Cited by in Crossref: 107] [Cited by in F6Publishing: 98] [Article Influence: 13.4] [Reference Citation Analysis]
122 Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
123 Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S761-6. [PMID: 31922534 DOI: 10.1093/ecco-jcc/jjaa003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
124 Kim MJ, Choe YH. Change in the treatment strategy for pediatric Crohn's disease. Korean J Pediatr 2010;53:830-3. [PMID: 21189967 DOI: 10.3345/kjp.2010.53.9.830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
125 Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002;20:639-52. [PMID: 12162753 DOI: 10.2165/00019053-200220100-00001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 3.0] [Reference Citation Analysis]
126 Johnston A, Guzman AM, Swindell WR, Wang F, Kang S, Gudjonsson JE. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol 2014;171:97-107. [PMID: 24601997 DOI: 10.1111/bjd.12937] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
127 Bamias G, Dahman MI, Arseneau KO, Guanzon M, Gruska D, Pizarro TT, Cominelli F. Intestinal-specific TNFα overexpression induces Crohn's-like ileitis in mice. PLoS One 2013;8:e72594. [PMID: 23977323 DOI: 10.1371/journal.pone.0072594] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
128 Araki T, Uchida K, Okita Y, Fujikawa H, Inoue M, Ohi M, Tanaka K, Inoue Y, Mohri Y, Kusunoki M. Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn's disease: a single-center paired case-control study. Surg Today 2014;44:291-6. [PMID: 23463537 DOI: 10.1007/s00595-013-0538-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
129 Vasilyeva E, Abdulkhakov S, Cherepnev G, Martynova E, Mayanskaya I, Valeeva A, Abdulkhakov R, Safina D, Khaiboullina S, Rizvanov A. Serum Cytokine Profiles in Children with Crohn's Disease. Mediators Inflamm 2016;2016:7420127. [PMID: 28070144 DOI: 10.1155/2016/7420127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
130 Yang H, Plevy SE, Taylor K, Tyan D, Fischel-Ghodsian N, McElree C, Targan SR, Rotter JI. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut. 1999;44:519-526. [PMID: 10075959 DOI: 10.1136/gut.44.4.519] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 3.1] [Reference Citation Analysis]
131 Dubinsky MC, Wang D, Picornell Y, Wrobel I, Katzir L, Quiros A, Dutridge D, Wahbeh G, Silber G, Bahar R, Mengesha E, Targan SR, Taylor KD, Rotter JI; Western Regional Research Alliance for Pediatric IBD. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis 2007;13:511-5. [PMID: 17309073 DOI: 10.1002/ibd.20126] [Cited by in Crossref: 99] [Cited by in F6Publishing: 108] [Article Influence: 6.6] [Reference Citation Analysis]
132 Click RE. Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chronic human diarrheal diseases. Virulence 2011;2:131-43. [PMID: 21460639 DOI: 10.4161/viru.2.2.15647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
133 van Montfrans C, Camoglio L, van Deventer SJ. Immunotherapy of Crohn's disease. Mediators Inflamm 1998;7:149-52. [PMID: 9705600 DOI: 10.1080/09629359891063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
134 Gerster R, Eloranta JJ, Hausmann M, Ruiz PA, Cosin-Roger J, Terhalle A, Ziegler U, Kullak-Ublick GA, von Eckardstein A, Rogler G. Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase. Cell Mol Gastroenterol Hepatol 2015;1:171-187.e1. [PMID: 28247863 DOI: 10.1016/j.jcmgh.2014.12.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
135 McVay LD, Keilbaugh SA, Wong TM, Kierstein S, Shin ME, Lehrke M, Lefterova MI, Shifflett DE, Barnes SL, Cominelli F. Absence of bacterially induced RELMbeta reduces injury in the dextran sodium sulfate model of colitis. J Clin Invest. 2006;116:2914-2923. [PMID: 17024245 DOI: 10.1172/jci28121] [Cited by in Crossref: 73] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
136 Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, Cassinotti A, Cazzola P, Markopoulos K, Massari A. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95:199-205. [PMID: 19815838 DOI: 10.3324/haematol.2009.009985] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 7.7] [Reference Citation Analysis]
137 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
138 Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2002;4:513-6. [PMID: 12441042 DOI: 10.1007/s11894-002-0028-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
139 Arseneau KO, Cominelli F. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther 2015;97:22-8. [PMID: 25670380 DOI: 10.1002/cpt.6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
140 Reiter G, Hassler N, Weber V, Falkenhagen D, Fringeli UP. In situ FTIR ATR spectroscopic study of the interaction of immobilized human tumor necrosis factor-alpha with a monoclonal antibody in aqueous environment. Biochim Biophys Acta 2004;1699:253-61. [PMID: 15158735 DOI: 10.1016/j.bbapap.2004.03.005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
141 Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 233] [Cited by in F6Publishing: 224] [Article Influence: 12.3] [Reference Citation Analysis]
142 Inoue S, Nakase H, Matsuura M, Mikami S, Ueno S, Uza N, Chiba T. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 2009;156:172-82. [PMID: 19220323 DOI: 10.1111/j.1365-2249.2008.03872.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
143 Atay K, Eyvazov H, Bozcan S, Eşkazan T, Demir N, Hatemi İ, Erzin Y, Çelik AF. The effect of concomitant ankylosing spondylitis on long-term outcome of patients with inflammatory bowel disease. Turk J Gastroenterol 2019;30:599-604. [PMID: 31290746 DOI: 10.5152/tjg.2019.17291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Murdoch T, O'Donnell S, Silverberg MS, Panaccione R. Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. Can J Gastroenterol Hepatol 2015;29:203-8. [PMID: 25965441 DOI: 10.1155/2015/389548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
145 Ang RL, Ting AT. Tumor necrosis factor-driven cell death in donor organ as a barrier to immunological tolerance. Curr Opin Organ Transplant 2019;24:12-9. [PMID: 30507704 DOI: 10.1097/MOT.0000000000000599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
147 Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep 2020;22:36. [PMID: 32542562 DOI: 10.1007/s11894-020-00773-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
148 Matta R, Barnard JA, Wancket LM, Yan J, Xue J, Grieves J, Frazier WJ, Nelin L, Cato AC, Liu Y. Knockout of Mkp-1 exacerbates colitis in Il-10-deficient mice. Am J Physiol Gastrointest Liver Physiol 2012;302:G1322-35. [PMID: 22461024 DOI: 10.1152/ajpgi.00018.2012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
149 Meijer MJ, Mieremet-Ooms MA, Hogezand RAV, Lamers CB, Hommes DW, Verspaget HW. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-α single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007; 13(21): 2960-2966 [PMID: 17589947 DOI: 10.3748/wjg.v13.i21.2960] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
150 Marques S, Garcia-gonzalo J, Botequim B, Ricardo A, Borges J, Tome M, Oliveira M. Assessing wildfire occurrence probability in Pinus pinaster Ait. stands in Portugal. Forest Syst 2012;21:111. [DOI: 10.5424/fs/2112211-11374] [Cited by in Crossref: 14] [Article Influence: 1.4] [Reference Citation Analysis]
151 Martín R, Miquel S, Ulmer J, Kechaou N, Langella P, Bermúdez-Humarán LG. Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease. Microb Cell Fact 2013;12:71. [PMID: 23876056 DOI: 10.1186/1475-2859-12-71] [Cited by in Crossref: 125] [Cited by in F6Publishing: 105] [Article Influence: 13.9] [Reference Citation Analysis]
152 de Buck van Overstraeten A, Wolthuis A, D’Hoore A. Surgery for Crohn’s disease in the era of biologicals: A reduced need or delayed verdict? World J Gastroenterol 2012; 18(29): 3828-3832 [PMID: 22876034 DOI: 10.3748/wjg.v18.i29.3828] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
153 Kammeyer A, Peters CP, Meijer SL, Te Velde AA. Anti-inflammatory effects of urocanic Acid derivatives in models ex vivo and in vivo of inflammatory bowel disease. ISRN Inflamm 2012;2012:898153. [PMID: 24049652 DOI: 10.5402/2012/898153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
154 Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F. Innate and adaptive immune responses related to IBD pathogenesis. Curr Gastroenterol Rep. 2007;9:508-512. [PMID: 18377804 DOI: 10.1007/s11894-007-0067-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
155 Assi K, Patterson S, Dedhar S, Owen D, Levings M, Salh B. Role of epithelial integrin-linked kinase in promoting intestinal inflammation: effects on CCL2, fibronectin and the T cell repertoire. BMC Immunol 2011;12:42. [PMID: 21806815 DOI: 10.1186/1471-2172-12-42] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
156 Louis E, Peeters M, Franchimont D, Seidel L, Fontaine F, Demolin G, Croes F, Dupont P, Davin L, Omri S. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clin Exp Immunol. 2000;119:64-68. [PMID: 10606965 DOI: 10.1046/j.1365-2249.2000.01106.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 2.5] [Reference Citation Analysis]
157 Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Yonsei Med J. 2016;57:1376-1385. [PMID: 27593865 DOI: 10.3349/ymj.2016.57.6.1376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
158 Fefferman DS, Shah SA, Alsahlil M, Gelrud A, Falchulk KR, Farrell RJ. Successful treatment of refractory esophageal Crohn's disease with infliximab. Dig Dis Sci 2001;46:1733-5. [PMID: 11508675 DOI: 10.1023/a:1010613823223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
159 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
160 Vasiliauskas E. Recent advances in the diagnosis and classification of inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:493-500. [PMID: 14602059 DOI: 10.1007/s11894-003-0039-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
161 Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. [PMID: 17299059 DOI: 10.1136/gut.2006.106781] [Cited by in Crossref: 649] [Cited by in F6Publishing: 609] [Article Influence: 43.3] [Reference Citation Analysis]
162 Travis S. Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2005;7:475-484. [PMID: 16313878 DOI: 10.1007/s11894-005-0079-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
163 Lai Y, Wang R, Chen X, Tang D, Hu Y, Cai J, Zhang Q, Hu H. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). Hum Vaccin Immunother 2017;13:1-10. [PMID: 28301271 DOI: 10.1080/21645515.2017.1286433] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
164 Giwa A, Ahmed R, Donner T, Yagita H, Hamad ARA. Editorial: Ying and Yang Members of the Tumor Necrosis Factor Superfamily: Friends or Foes in Immune-Mediated Diseases and Cancer. Front Immunol 2017;8:1584. [PMID: 29218044 DOI: 10.3389/fimmu.2017.01584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
165 D'haens G. The impact of anti-TNF (Infliximab or RemicadeR) on the surgical management of Crohn's disease. Colorect Dis 2001;3:7-10. [DOI: 10.1046/j.1463-1318.2001.003s2007.x] [Reference Citation Analysis]
166 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
167 Brown KK, Heitmeyer SA, Hookfin EB, Hsieh L, Buchalova M, Taiwo YO, Janusz MJ. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond) 2008;5:22. [PMID: 19055838 DOI: 10.1186/1476-9255-5-22] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
168 Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25:406-410. [PMID: 15309501 DOI: 10.1007/s00296-004-0467-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 4.3] [Reference Citation Analysis]
169 Norton BA, Thomas R, Lomax KG, Dudley-Brown S. Patient perspectives on the impact of Crohn's disease: results from group interviews. Patient Prefer Adherence 2012;6:509-20. [PMID: 22879737 DOI: 10.2147/PPA.S32690] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
170 Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn’s disease. Therap Adv Gastroenterol. 2010;3:179-189. [PMID: 21180600 DOI: 10.1177/1756283x09357579] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
171 Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015;21:1329-1340. [PMID: 25989338 DOI: 10.1097/mib.0000000000000366] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
172 Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33-52. [PMID: 27022240 DOI: 10.2147/BTT.S71679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
173 Nikolaus S, Schreiber S. [Anti-TNF biologics in the treatment of chronic inflammatory bowel disease]. Internist (Berl) 2008;49:947-8, 950-3. [PMID: 18584139 DOI: 10.1007/s00108-008-2058-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
174 Rivera-Nieves J, Burcin TL, Olson TS, Morris MA, McDuffie M, Cominelli F, Ley K. Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med. 2006;203:907-917. [PMID: 16567389 DOI: 10.1084/jem.20052530] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
175 Hofstaedter F. Granuloma formation in the different phenotypes of Crohn's disease. Gut 2005;54:180-1. [PMID: 15647175 DOI: 10.1136/gut.2004.048082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
176 Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol. 2007;42:16-25. [PMID: 17322989 DOI: 10.1007/s00535-006-1995-7] [Cited by in Crossref: 160] [Cited by in F6Publishing: 155] [Article Influence: 10.7] [Reference Citation Analysis]
177 Sorrentino D, Avellini C, Beltrami CA, Pasqual E, Zearo E. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006;21:276-81. [PMID: 15951989 DOI: 10.1007/s00384-005-0739-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
178 Feldman AM, Kubota T, You Li Y, Wagner D, Combes A, Mctiernan C. EVIDENCE OF PHENOTYPIC ALTERATION AS A CAUSE OF SYSTOLIC DYSFUNCTION IN THE FAILING HEART. Cardiology Clinics 1998;16:677-89. [DOI: 10.1016/s0733-8651(05)70044-8] [Reference Citation Analysis]
179 Mueller C. Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 2002;105:1-8. [PMID: 11849309 DOI: 10.1046/j.1365-2567.2002.01329.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
180 Freeman HJ. Use of the Crohn’s disease activity index in clinical trials of biological agents. World J Gastroenterol 2008; 14(26): 4127-4130 [PMID: 18636655 DOI: 10.3748/wjg.14.4127] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
181 Iijima H, Kobayashi T, Nagasaka M, Shinzaki S, Kitamura K, Suzuki Y, Watanabe M, Hibi T. Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn's Disease. Inflamm Intest Dis 2020;5:78-83. [PMID: 32596258 DOI: 10.1159/000506337] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
182 Ancowitz B, Shah SA. Infusion services in the gastroenterology practice. Gastrointest Endosc Clin N Am 2006;16:727-42. [PMID: 17098619 DOI: 10.1016/j.giec.2006.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
183 Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00856-2. [PMID: 34903497 DOI: 10.1016/j.dld.2021.11.014] [Reference Citation Analysis]
184 Hendler SA, Cohen BL, Colombel JF, Sands BE, Mayer L, Agarwal S. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. J Crohns Colitis. 2015;9:266-275. [PMID: 25540149 DOI: 10.1093/ecco-jcc/jju026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
185 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 937] [Cited by in F6Publishing: 820] [Article Influence: 133.9] [Reference Citation Analysis]
186 Schön MP. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol 2019;10:1764. [PMID: 31402919 DOI: 10.3389/fimmu.2019.01764] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
187 Everett SM, Hamlin PJ. Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011;2:144-50. [PMID: 28839599 DOI: 10.1136/fg.2010.003566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
188 Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, De Keyser F, Veys EM. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34. [PMID: 12922954 DOI: 10.1136/ard.62.9.829] [Cited by in Crossref: 110] [Cited by in F6Publishing: 93] [Article Influence: 5.8] [Reference Citation Analysis]
189 Rampton DS. Management of Crohn's disease. BMJ. 1999;319:1480-1485. [PMID: 10582935 DOI: 10.1136/bmj.319.7223.1480] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
190 Shah P, Sundaram V, Björnsson E. Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. Hepatol Commun 2020;4:172-84. [PMID: 32025603 DOI: 10.1002/hep4.1465] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
191 Laudien M, Ambrosch P, Till A, Podschun R, Lamprecht P. [Diagnosis, therapy and current research aspects of selected chronic inflammatory diseases with head and neck involvement]. Z Rheumatol 2008;67:397-406. [PMID: 18600330 DOI: 10.1007/s00393-008-0324-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
192 Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10:301-16. [PMID: 20414204 DOI: 10.1038/nri2761] [Cited by in Crossref: 604] [Cited by in F6Publishing: 553] [Article Influence: 50.3] [Reference Citation Analysis]
193 Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 2007;8:5. [PMID: 17397543 DOI: 10.1186/1471-2172-8-5] [Cited by in Crossref: 190] [Cited by in F6Publishing: 183] [Article Influence: 12.7] [Reference Citation Analysis]
194 ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211. [PMID: 11788561 DOI: 10.1136/gut.50.2.206] [Cited by in Crossref: 370] [Cited by in F6Publishing: 358] [Article Influence: 18.5] [Reference Citation Analysis]
195 Nikolaus S, Schreiber S, Fölsch UR. [Pharmacologic therapy for inflammatory bowel diseases: hopes, disappointments]. Internist (Berl) 2005;46:586-91. [PMID: 15806413 DOI: 10.1007/s00108-005-1386-9] [Reference Citation Analysis]
196 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
197 Bhol KC, Tracey DE, Lemos BR, Lyng GD, Erlich EC, Keane DM, Quesenberry MS, Holdorf AD, Schlehuber LD, Clark SA, Fox BS. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2273-81. [PMID: 23949620 DOI: 10.1097/MIB.0b013e3182a11958] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
198 Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazalé T, Raupach B, Eckert J, Schumann RR, Enders C, Sonnenborn U. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun. 2005;73:1452-1465. [PMID: 15731043 DOI: 10.1128/iai.73.3.1452-1465.2005] [Cited by in Crossref: 84] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
199 Rivera-Nieves J. Targeting leukocyte traffic: A new era for the treatment of Inflammatory bowel disease. J Crohns Colitis 2018;12:S631-2. [PMID: 30137310 DOI: 10.1093/ecco-jcc/jjy067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
200 Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: how much is too much? Curr Opin Gastroenterol 2012;28:341-8. [PMID: 22573191 DOI: 10.1097/MOG.0b013e328354567f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
201 Matsuoka K, Inoue N, Sato T, Okamoto S, Hisamatsu T, Kishi Y, Sakuraba A, Hitotsumatsu O, Ogata H, Koganei K, Fukushima T, Kanai T, Watanabe M, Ishii H, Hibi T. T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut. 2004;53:1303-1308. [PMID: 15306590 DOI: 10.1136/gut.2003.024190] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 5.4] [Reference Citation Analysis]
202 Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, Weisshof R, Goren I, Rabinowitz K, Waterman M, Yanai H, Dotan I, Sabo E, Chowers Y, Khatri P, Shen-Orr SS; Israeli IBD research Network (IIRN). Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD. Gut 2019;68:604-14. [PMID: 29618496 DOI: 10.1136/gutjnl-2017-315494] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 17.5] [Reference Citation Analysis]
203 Rahbour G, Hart AL, Al-Hassi HO, Ullah MR, Gabe SM, Knight SC, Warusavitarne J, Vaizey CJ. Prospective study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas. BMC Surg 2011;11:12. [PMID: 21619579 DOI: 10.1186/1471-2482-11-12] [Reference Citation Analysis]
204 Saeed M, Hullur H, Salem A, Ali A, Sahib Y, Ashfaq M. Improved Biochemical Parameters in Patients Who Undergo Early Resection in Isolated Ileocaecal Crohn's Disease. Surg Res Pract 2017;2017:4396573. [PMID: 28776001 DOI: 10.1155/2017/4396573] [Reference Citation Analysis]
205 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
206 Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, Saermark T. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43. [PMID: 12077089 DOI: 10.1136/gut.51.1.37] [Cited by in Crossref: 131] [Cited by in F6Publishing: 132] [Article Influence: 6.6] [Reference Citation Analysis]
207 Ruffolo C, Citton M, Scarpa M, Angriman I, Massani M, Caratozzolo E, Bassi N. Perianal Crohn’s disease: Is there something new? World J Gastroenterol 2011; 17(15): 1939-1946 [PMID: 21528071 DOI: 10.3748/wjg.v17.i15.1939] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
208 Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12(23): 3657-3667 [PMID: 16773681 DOI: 10.3748/wjg.v12.i23.3657] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
209 Zaboli P, Abdollahi M, Mozaffari S, Nikfar S. Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis. J Res Pharm Pract 2017;6:135-44. [PMID: 29026838 DOI: 10.4103/jrpp.JRPP_17_46] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
210 Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: A comparison of Eastern and Western perspectives. World J Gastroenterol 2014; 20(33): 11525-11537 [PMID: 25206259 DOI: 10.3748/wjg.v20.i33.11525] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 65] [Article Influence: 8.3] [Reference Citation Analysis]
211 Kotze PG, Saab MP, Saab B, da Silva Kotze LM, Olandoski M, Pinheiro LV, Martinez CA, Ayrizono ML, Magro DO, Coy CS. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. Dig Dis Sci 2017;62:456-64. [PMID: 27933472 DOI: 10.1007/s10620-016-4400-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
212 Schreiber S. Activation of nuclear factor kappaB as a target for anti-inflammatory therapy. Gut 1999;44:309-10. [PMID: 10026311 DOI: 10.1136/gut.44.3.309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
213 Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004;63:755-8. [PMID: 15194567 DOI: 10.1136/ard.2004.020719] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 3.8] [Reference Citation Analysis]
214 Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis 2019;13:1227-33. [PMID: 30726897 DOI: 10.1093/ecco-jcc/jjz031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
215 Antoni CE, Manger B. [Biologicals: a new therapeutic approach for inflammatory diseases]. Internist (Berl) 2004;45 Suppl 1:S31-7. [PMID: 15160244 DOI: 10.1007/s00108-004-1225-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6 Suppl 1:17-27. [PMID: 22009609 DOI: 10.1007/s11739-011-0673-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
217 Fefferman DS, Shah SA, Alsahlil M, Gelrud A, Falchulk KR, Farrell RJ. Successful treatment of refractory esophageal Crohn's disease with infliximab. Dig Dis Sci 2001;46:1733-5. [PMID: 11508675 DOI: 10.1023/a:1010613823223] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
218 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267-276. [PMID: 21108015 DOI: 10.1007/s11605-010-1396-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
219 Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory Bowel Disease. Dtsch Arztebl Int 2016;113:72-82. [PMID: 26900160 DOI: 10.3238/arztebl.2016.0072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
220 Hitraya E, Schaible T. Anti – Tumor Necrosis Factor Therapies In Crohn’s Disease And Rheumatoid Arthritis. In: Ciliberto G, Savino R, editors. Cytokine Inhibitors. CRC Press; 2000. [DOI: 10.1201/9780203904244.ch4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
221 Chan AC, Behrens TW. Personalizing medicine for autoimmune and inflammatory diseases. Nat Immunol. 2013;14:106-109. [PMID: 23334822 DOI: 10.1038/ni.2473] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
222 Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 2016; 22(42): 9300-9313 [PMID: 27895418 DOI: 10.3748/wjg.v22.i42.9300] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 83] [Article Influence: 15.2] [Reference Citation Analysis]
223 Moretti D, Cianchi I, Vannucci G, Cimaz R, Simonini G. Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report. Case Rep Rheumatol 2013;2013:595890. [PMID: 24191219 DOI: 10.1155/2013/595890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
224 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
225 Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut. 2004;53:70-77. [PMID: 14684579 DOI: 10.1136/gut.53.1.70] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 7.1] [Reference Citation Analysis]
226 Wright KL, Weaver SA, Patel K, Coopman K, Feeney M, Kolios G, Robertson DA, Ward SG. Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. Br J Pharmacol 2004;141:1091-7. [PMID: 15023855 DOI: 10.1038/sj.bjp.0705719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
227 Ichikawa R, Lamb CA, Eastham-Anderson J, Scherl A, Raffals L, Faubion WA, Bennett MR, Long AK, Mansfield JC, Kirby JA, Keir ME. AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation. J Crohns Colitis 2018;12:1191-9. [PMID: 29912405 DOI: 10.1093/ecco-jcc/jjy084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
228 Patil SA, Rustgi A, Langenberg P, Cross RK. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci 2013;58:209-15. [PMID: 23014844 DOI: 10.1007/s10620-012-2323-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
229 Drewe E, Powell RJ. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55:81-5. [PMID: 11864998 DOI: 10.1136/jcp.55.2.81] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
230 Piccoli R, Olson KA, Vallee BL, Fett JW. Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc Natl Acad Sci U S A 1998;95:4579-83. [PMID: 9539780 DOI: 10.1073/pnas.95.8.4579] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
231 de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm. 2015;2015:493012. [PMID: 26339135 DOI: 10.1155/2015/493012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 11.9] [Reference Citation Analysis]
232 Carty E, De Brabander M, Feakins RM, Rampton DS. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut. 2000;46:487-492. [PMID: 10716677 DOI: 10.1136/gut.46.4.487] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 3.2] [Reference Citation Analysis]
233 Williams AM, Whiting CV, Bonhagen K, Reimann J, Bregenholt S, Claesson MH, Bland PW. Tumour necrosis factor-alpha (TNF-alpha) transcription and translation in the CD4+ T cell-transplanted scid mouse model of colitis. Clin Exp Immunol 1999;116:415-24. [PMID: 10361228 DOI: 10.1046/j.1365-2249.1999.00915.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
234 Locher MR, Alam A. Acute Psychosis in an Adolescent Treated With Infliximab for Crohn's Disease. Prim Care Companion CNS Disord 2015;17. [PMID: 26693043 DOI: 10.4088/PCC.15l01781] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
235 Azer SA, Azer S. What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. BMJ Open. 2018;8:e021233. [PMID: 30002009 DOI: 10.1136/bmjopen-2017-021233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
236 Keller JJ, Wang J, Hwang YL, Chou CC, Wang LH, Hsu JL, Bai CH, Chiou HY. Increased risk of stroke among patients with Crohn's disease: a population-based matched cohort study. Int J Colorectal Dis 2015;30:645-53. [PMID: 25608496 DOI: 10.1007/s00384-015-2132-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
237 Parray FQ, Wani ML, Bijli AH, Thakur N, Irshad I; Nayeem-ul-Hassan. Crohn's disease: a surgeon's perspective. Saudi J Gastroenterol 2011;17:6-15. [PMID: 21196646 DOI: 10.4103/1319-3767.74430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
238 Wu G, Yang Y, Liu M, Wang Y, Guo Q. Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease. Front Pharmacol 2021;12:655865. [PMID: 33935772 DOI: 10.3389/fphar.2021.655865] [Reference Citation Analysis]
239 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
240 Suzuki K, Nakajima H, Ikeda K, Maezawa Y, Suto A, Takatori H, Saito Y, Iwamoto I. IL-4-Stat6 signaling induces tristetraprolin expression and inhibits TNF-alpha production in mast cells. J Exp Med 2003;198:1717-27. [PMID: 14638848 DOI: 10.1084/jem.20031701] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 2.5] [Reference Citation Analysis]
241 Wang XY, Wang B, Wen YM. From therapeutic antibodies to immune complex vaccines. NPJ Vaccines. 2019;4:2. [PMID: 30675393 DOI: 10.1038/s41541-018-0095-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
242 Jungbeck M, Daller B, Federhofer J, Wege AK, Wimmer N, Männel DN, Hehlgans T. Neutralization of LIGHT ameliorates acute dextran sodium sulphate-induced intestinal inflammation. Immunology 2009;128:451-8. [PMID: 20067544 DOI: 10.1111/j.1365-2567.2009.03131.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
243 Ho SL, Niu F, Pola S, Velayos FS, Ning X, Hui RL. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. BioDrugs 2020;34:395-404. [PMID: 32103457 DOI: 10.1007/s40259-020-00409-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
244 Rampton DS, Phil D. New treatments for inflammatory bowel disease. World J Gastroenterol 1998; 4(5): 369-376 [PMID: 11819324 DOI: 10.3748/wjg.v4.i5.369] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
245 Rol Á, Todorovski T, Martin-Malpartida P, Escolà A, Gonzalez-Rey E, Aragón E, Verdaguer X, Vallès-Miret M, Farrera-Sinfreu J, Puig E, Fernández-Carneado J, Ponsati B, Delgado M, Riera A, Macias MJ. Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease. Nat Commun 2021;12:1869. [PMID: 33767180 DOI: 10.1038/s41467-021-22076-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Slattery E, Keegan D, O'Donoghue D. Anorectal stenosis after treatment with tumor necrosis factor alpha antibodies: a case series. J Med Case Rep 2010;4:226. [PMID: 20659338 DOI: 10.1186/1752-1947-4-226] [Reference Citation Analysis]
247 Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403. [PMID: 10940278 DOI: 10.1136/gut.47.3.397] [Cited by in Crossref: 744] [Cited by in F6Publishing: 701] [Article Influence: 33.8] [Reference Citation Analysis]
248 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
249 Alrashid AI, Brown RD, Mihalov ML, Sekosan M, Pastika BJ, Venu RP. Crohn's disease involving the lung: resolution with infliximab. Dig Dis Sci 2001;46:1736-9. [PMID: 11508676 DOI: 10.1023/a:1010665807294] [Cited by in Crossref: 34] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
250 Kamata N, Oshitani N, Watanabe K, Watanabe K, Hosomi S, Noguchi A, Yukawa T, Yamagami H, Shiba M, Tanigawa T, Watanabe T, Tominaga K, Fujiwara Y, Arakawa T. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response. Dig Dis Sci 2015;60:1382-8. [PMID: 25532505 DOI: 10.1007/s10620-014-3493-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
251 Weigmann B, Neurath MF. T-bet and mucosal Th1 responses in the gastrointestinal tract. Gut 2002;51:301-3. [PMID: 12171942 DOI: 10.1136/gut.51.3.301] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
252 Watanabe T, Kitani A, Strober W. NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease. Gut 2005;54:1515-8. [PMID: 16227353 DOI: 10.1136/gut.2005.071795] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
253 Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant 2009;15:777-84. [PMID: 19539208 DOI: 10.1016/j.bbmt.2009.03.012] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
254 Gratz R, Becker S, Sokolowski N, Schumann M, Bass D, Malnick SD. Murine monoclonal anti-tNF antibody administration has a beneficial effect on inflammatory bowel disease that develops in IL-10 knockout mice. Dig Dis Sci. 2002;47:1723-1727. [PMID: 12184521 DOI: 10.1023/A:1016476024293] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
255 Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
256 Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:99-106. [PMID: 21180594 DOI: 10.1177/1756283x09356872] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
257 Kaler P, Owusu BY, Augenlicht L, Klampfer L. The Role of STAT1 for Crosstalk between Fibroblasts and Colon Cancer Cells. Front Oncol 2014;4:88. [PMID: 24818101 DOI: 10.3389/fonc.2014.00088] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
258 Catt H, Hughes D, Kirkham JJ, Bodger K. Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. Aliment Pharmacol Ther 2019;49:978-96. [PMID: 30828852 DOI: 10.1111/apt.15174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
259 MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2016;11:CD007572. [PMID: 27885650 DOI: 10.1002/14651858.CD007572.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
260 Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, Yoshinari T, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol 2014;49:254-62. [DOI: 10.1007/s00535-013-0807-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
261 Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, Yamamoto K. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 2006;8:R166. [PMID: 17078892 DOI: 10.1186/ar2074] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 6.5] [Reference Citation Analysis]
262 Singh S, Heien HC, Sangaralingham LR, Schilz SR, Kappelman MD, Shah ND, Loftus EV Jr. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2016;14:1120-1129.e6. [PMID: 27058635 DOI: 10.1016/j.cgh.2016.03.038] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
263 Prehn JL, Landers C, Muller GW, Man HW, Stirling DI, Targan SR. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol 2001;21:357-64. [PMID: 11720008 DOI: 10.1023/a:1012292703871] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
264 Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Böcker U, Böhm S, Büning C. Significant differences between Crohn’s disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. Dig Dis Sci. 2010;55:1066-1078. [PMID: 19513841 DOI: 10.1007/s10620-009-0846-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
265 Verdù EF, Bercik P, Cukrowska B, Farre-Castany MA, Bouzourene H, Saraga E, Blum AL, Corthésy-Theulaz I, Tlaskalova-Hogenova H, Michetti P. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Clin Exp Immunol. 2000;120:46-50. [PMID: 10759762 DOI: 10.1046/j.1365-2249.2000.01170.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
266 Schneider H, Braun A, Füllekrug J, Stremmel W, Ehehalt R. Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation. Int J Mol Sci 2010;11:4149-64. [PMID: 21152327 DOI: 10.3390/ijms11104149] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
267 Beattie RM. Therapy of Crohn's disease in childhood. Paediatr Drugs. 2000;2:193-203. [PMID: 10937470 DOI: 10.2165/00128072-200002030-00004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
268 Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs 2019;79:1053-63. [PMID: 31183768 DOI: 10.1007/s40265-019-01141-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
269 Lakatos L, Lakatos PL. [Medical therapy of inflammatory bowel diseases: Crohn's disease]. Orv Hetil 2007;148:1107-14. [PMID: 17561480 DOI: 10.1556/OH.2007.28062] [Reference Citation Analysis]
270 Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP, Weisman MH. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 2012;14:R261. [PMID: 23194008 DOI: 10.1186/ar4106] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
271 Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999;58 Suppl 1:I32-9. [PMID: 10577971 DOI: 10.1136/ard.58.2008.i32] [Cited by in Crossref: 115] [Cited by in F6Publishing: 112] [Article Influence: 5.2] [Reference Citation Analysis]
272 Fiocchi C. TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest. 2001;108:523-526. [PMID: 11518725 DOI: 10.1172/jci13863] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
273 Suzuki M, Nagaishi T, Yamazaki M, Onizawa M, Watabe T, Sakamaki Y, Ichinose S, Totsuka M, Oshima S, Okamoto R. Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the epithelial cells regulates the development of colitis-associated carcinogenesis. PLoS One. 2014;9:e88369. [PMID: 24520376 DOI: 10.1371/journal.pone.0088369] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
274 Behm BW, Bickston SJ. Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis. Curr Treat Options Gastroenterol. 2007;10:171-177. [PMID: 17547855 DOI: 10.1007/s11938-007-0010-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
275 Cichon C, Sabharwal H, Rüter C, Schmidt MA. MicroRNAs regulate tight junction proteins and modulate epithelial/endothelial barrier functions. Tissue Barriers. 2014;2:e944446. [PMID: 25610754 DOI: 10.4161/21688362.2014.944446] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
276 Murphy CC, Duncan L, Forrester JV, Dick AD. Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol 2004;88:412-6. [PMID: 14977779 DOI: 10.1136/bjo.2003.028506] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
277 Zhang H, Shi N, Diao Z, Chen Y, Zhang Y. Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future. Genes Dis 2021;8:38-47. [PMID: 33569512 DOI: 10.1016/j.gendis.2020.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
278 Ishii D, Schenk AD, Baba S, Fairchild RL. Role of TNFalpha in early chemokine production and leukocyte infiltration into heart allografts. Am J Transplant 2010;10:59-68. [PMID: 19958333 DOI: 10.1111/j.1600-6143.2009.02921.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
279 Loomes DE, Teshima C, Jacobs P, Fedorak RN. Health care resource use and costs in Crohn’s disease before and after infliximab therapy. Can J Gastroenterol. 2011;25:497-502. [PMID: 21912761 DOI: 10.1155/2011/157604] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
280 Schümann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N, Tiegs G. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol. 2000;157:1671-1683. [PMID: 11073826 DOI: 10.1016/s0002-9440(10)64804-3] [Cited by in Crossref: 205] [Cited by in F6Publishing: 71] [Article Influence: 9.3] [Reference Citation Analysis]
281 Hirai F, Ishihara H, Yada S, Esaki M, Ohwan T, Nozaki R, Ashizuka S, Inatsu H, Ohi H, Aoyagi K, Mizuta Y, Matsumoto T, Matsui T. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults. Dig Dis Sci 2013;58:1329-34. [PMID: 22926500 DOI: 10.1007/s10620-012-2374-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
282 Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.04337253/suppl_5/v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
283 Steeland S, Libert C, Vandenbroucke RE. A New Venue of TNF Targeting. Int J Mol Sci 2018;19:E1442. [PMID: 29751683 DOI: 10.3390/ijms19051442] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
284 Tran CN, Lundy SK, White PT, Endres JL, Motyl CD, Gupta R, Wilke CM, Shelden EA, Chung KC, Urquhart AG, Fox DA. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am J Pathol 2007;171:1588-98. [PMID: 17823284 DOI: 10.2353/ajpath.2007.070004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
285 Clarke K, Chintanaboina J. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease. Clin Rev Allergy Immunol 2019;57:179-93. [PMID: 29754190 DOI: 10.1007/s12016-018-8690-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
286 Chen P, Huang NT, Chung MT, Cornell TT, Kurabayashi K. Label-free cytokine micro- and nano-biosensing towards personalized medicine of systemic inflammatory disorders. Adv Drug Deliv Rev 2015;95:90-103. [PMID: 26408791 DOI: 10.1016/j.addr.2015.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
287 Collins CB, Aherne CM, McNamee EN, Lebsack MD, Eltzschig H, Jedlicka P, Rivera-Nieves J. Flt3 ligand expands CD103⁺ dendritic cells and FoxP3⁺ T regulatory cells, and attenuates Crohn's-like murine ileitis. Gut 2012;61:1154-62. [PMID: 22068168 DOI: 10.1136/gutjnl-2011-300820] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
288 Hirohata S, Kikuchi H. Behçet's disease. Arthritis Res Ther 2003;5:139-46. [PMID: 12723980 DOI: 10.1186/ar757] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
289 Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53:1485-1493. [PMID: 15361500 DOI: 10.1136/gut.2003.035253] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
290 Albright CA, Sartor RB, Tonkonogy SL. Endogenous antigen presenting cell-derived IL-10 inhibits T lymphocyte responses to commensal enteric bacteria. Immunol Lett 2009;123:77-87. [PMID: 19428554 DOI: 10.1016/j.imlet.2009.02.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
291 Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007;56:1181-3. [PMID: 17698862 DOI: 10.1136/gut.2006.115980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
292 Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kühbacher T, Hämling J, Fölsch UR, Seegert D. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut. 2002;51:379-385. [PMID: 12171960 DOI: 10.1136/gut.51.3.379] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 6.8] [Reference Citation Analysis]
293 Matsuzaki K, Tsuzuki Y, Matsunaga H, Inoue T, Miyazaki J, Hokari R, Okada Y, Kawaguchi A, Nagao S, Itoh K. In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin Exp Immunol. 2005;140:22-31. [PMID: 15762871 DOI: 10.1111/j.1365-2249.2005.02742.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 2.5] [Reference Citation Analysis]
294 Treede I, Braun A, Sparla R, Kühnel M, Giese T, Turner JR, Anes E, Kulaksiz H, Füllekrug J, Stremmel W, Griffiths G, Ehehalt R. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem 2007;282:27155-64. [PMID: 17636253 DOI: 10.1074/jbc.M704408200] [Cited by in Crossref: 144] [Cited by in F6Publishing: 62] [Article Influence: 9.6] [Reference Citation Analysis]
295 Ruemmele FM, Beaulieu JF, Dionne S, Levy E, Seidman EG, Cerf-Bensussan N, Lentze MJ. Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factor alpha. Gut 2002;51:842-8. [PMID: 12427787 DOI: 10.1136/gut.51.6.842] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 3.7] [Reference Citation Analysis]
296 Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33. [PMID: 16120759 DOI: 10.1136/gut.2005.075937] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
297 Ramarapu S. Anesthetizing a Patient with Escalating Cardiac Enzyme Levels for Urgent Noncardiac Surgery: Clinical and Ethical Concerns. A A Case Rep 2015;5:29-31. [PMID: 26171740 DOI: 10.1213/XAA.0000000000000168] [Reference Citation Analysis]
298 Isaacs KL. Crohn's disease of the esophagus. Curr Treat Options Gastroenterol 2007;10:61-70. [PMID: 17298766 DOI: 10.1007/s11938-007-0058-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
299 Labbé C, Boucher G, Foisy S, Alikashani A, Nkwimi H, David G, Beaudoin M, Goyette P, Charron G, Xavier RJ, Rioux JD. Genome-wide expression profiling implicates a MAST3-regulated gene set in colonic mucosal inflammation of ulcerative colitis patients. Inflamm Bowel Dis 2012;18:1072-80. [PMID: 21994190 DOI: 10.1002/ibd.21887] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
300 Ruffolo C, Scarpa M, Faggian D, Romanato G, De Pellegrin A, Filosa T, Prando D, Polese L, Scopelliti M, Pilon F, Ossi E, Frego M, D'Amico DF, Angriman I. Cytokine network in chronic perianal Crohn's disease and indeterminate colitis after colectomy. J Gastrointest Surg. 2007;11:16-21. [PMID: 17390181 DOI: 10.1007/s11605-006-0021-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
301 Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY. Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007;292:G590-G598. [PMID: 17068119 DOI: 10.1152/ajpgi.00252.2006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 4.7] [Reference Citation Analysis]
302 Chowers Y. Taking Crohn's disease personally. Rambam Maimonides Med J 2013;4:e0011. [PMID: 23908861 DOI: 10.5041/RMMJ.10111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
303 Stallmach A, Wittig BM, Moser C, Fischinger J, Duchmann R, Zeitz M. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut. 2003;52:377-382. [PMID: 12584219 DOI: 10.1136/gut.52.3.377] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
304 Hughes A, Marshall JK, Moretti ME, Ungar WJ. A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. J Can Assoc Gastroenterol 2021;4:48. [PMID: 33644677 DOI: 10.1093/jcag/gwz045] [Reference Citation Analysis]
305 Swaminath A, Lebwohl B, Capiak KM, Present DH. Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn’s disease: a US national practice survey comparing experts and non-experts. Dig Dis Sci. 2011;56:1160-1164. [PMID: 21181440 DOI: 10.1007/s10620-010-1530-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
306 Sprakes MB, Hamlin PJ. Anti-tumour necrosis factor-alpha therapies in Crohn's disease. Br J Hosp Med (Lond) 2009;70:644-7. [PMID: 20081592 DOI: 10.12968/hmed.2009.70.11.45055] [Reference Citation Analysis]
307 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19(17): 2591-2602 [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
308 Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019;2:e1-e34. [PMID: 31294378 DOI: 10.1093/jcag/gwz019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
309 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
310 Soni D, Salh B. A neutraceutical by design: the clinical application of curcumin in colonic inflammation and cancer. Scientifica (Cairo) 2012;2012:757890. [PMID: 24278738 DOI: 10.6064/2012/757890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
311 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
312 Muley MM, Krustev E, McDougall JJ. Preclinical Assessment of Inflammatory Pain. CNS Neurosci Ther 2016;22:88-101. [PMID: 26663896 DOI: 10.1111/cns.12486] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
313 Kolesnick R, Xing HR. Inflammatory bowel disease reveals the kinase activity of KSR1. J Clin Invest 2004;114:1233-7. [PMID: 15520853 DOI: 10.1172/JCI23441] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
314 Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut. 2002;50:196-200. [PMID: 11788559 DOI: 10.1136/gut.50.2.196] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 4.5] [Reference Citation Analysis]
315 Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol 2015; 21(44): 12519-12543 [PMID: 26640330 DOI: 10.3748/wjg.v21.i44.12519] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
316 Yamada H. Current perspectives on the role of IL-17 in autoimmune disease. J Inflamm Res 2010;3:33-44. [PMID: 22096355 DOI: 10.2147/jir.s6375] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
317 Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012;10:46-51. [PMID: 21963958 DOI: 10.1016/j.cgh.2011.09.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
318 Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn’s disease. World J Gastroenterol 2009; 15(35): 4449-4452 [PMID: 19764100 DOI: 10.3748/wjg.15.4449] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
319 Song YN, Zheng P, Xiao JH, Lu ZJ. Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials. Eur J Clin Pharmacol 2014;70:907-14. [PMID: 24880961 DOI: 10.1007/s00228-014-1702-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
320 Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12(29): 4628-4635 [PMID: 16937430 DOI: 10.3748/wjg.v12.i29.4628] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
321 Konrad A, Mähler M, Arni S, Flogerzi B, Klingelhöfer S, Seibold F. Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis 2005;20:9-17. [PMID: 15338166 DOI: 10.1007/s00384-004-0619-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
322 Jiang H, Deng CS, Zhang M, Xia J. Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 2006; 12(24): 3848-3853 [PMID: 16804969 DOI: 10.3748/wjg.v12.i24.3848] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
323 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
324 Ye D, Guo S, Al-Sadi R, Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology. 2011;141:1323-1333. [PMID: 21763238 DOI: 10.1053/j.gastro.2011. 07.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
325 Marjoram L, Alvers A, Deerhake ME, Bagwell J, Mankiewicz J, Cocchiaro JL, Beerman RW, Willer J, Sumigray KD, Katsanis N, Tobin DM, Rawls JF, Goll MG, Bagnat M. Epigenetic control of intestinal barrier function and inflammation in zebrafish. Proc Natl Acad Sci U S A 2015;112:2770-5. [PMID: 25730872 DOI: 10.1073/pnas.1424089112] [Cited by in Crossref: 112] [Cited by in F6Publishing: 91] [Article Influence: 16.0] [Reference Citation Analysis]
326 Gordic S, Bane O, Kihira S, Peti S, Hectors S, Torres J, Cho J, Colombel JF, Taouli B. Evaluation of ileal Crohn's disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results. Eur J Radiol Open 2020;7:100217. [PMID: 33102636 DOI: 10.1016/j.ejro.2020.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
327 Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res 2002;4 Suppl 2:S34-40. [PMID: 12110156 DOI: 10.1186/ar552] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
328 Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, Weiss G, Tilg H. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A 2005;102:13622-7. [PMID: 16174751 DOI: 10.1073/pnas.0501758102] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
329 Meissner K, Distel H, Mitzdorf U. Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials. BMC Med 2007;5:3. [PMID: 17371590 DOI: 10.1186/1741-7015-5-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
330 Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 2011;226:2438-47. [PMID: 21660967 DOI: 10.1002/jcp.22593] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
331 Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, Brzezinski A, Strong SA, Hammel J, Kiran RP. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg. 2008;12:1738-1744. [PMID: 18709420 DOI: 10.1007/s11605-008-0646-0] [Cited by in Crossref: 188] [Cited by in F6Publishing: 160] [Article Influence: 13.4] [Reference Citation Analysis]
332 Carty E, Rampton DS. Evaluation of new therapies for inflammatory bowel disease. Br J Clin Pharmacol 2003;56:351-61. [PMID: 12968979 DOI: 10.1046/j.1365-2125.2003.01965.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
333 DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies. Curr Gastroenterol Rep 2016;18:13. [PMID: 26908281 DOI: 10.1007/s11894-016-0487-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
334 Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Büschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn‘s disease. Gut. 1999;44:625-628. [PMID: 10205197 DOI: 10.1136/gut.44.5.625] [Cited by in Crossref: 147] [Cited by in F6Publishing: 110] [Article Influence: 6.4] [Reference Citation Analysis]
335 Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53. [PMID: 15972298 DOI: 10.1136/gut.2005.068809] [Cited by in Crossref: 354] [Cited by in F6Publishing: 318] [Article Influence: 20.8] [Reference Citation Analysis]
336 d'Ettorre G, Rossi G, Scagnolari C, Andreotti M, Giustini N, Serafino S, Schietroma I, Scheri GC, Fard SN, Trinchieri V, Mastromarino P, Selvaggi C, Scarpona S, Fanello G, Fiocca F, Ceccarelli G, Antonelli G, Brenchley JM, Vullo V. Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients. Immun Inflamm Dis 2017;5:244-60. [PMID: 28474815 DOI: 10.1002/iid3.160] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
337 Harris KG, Chang EB. The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease. Clin Sci (Lond) 2018;132:2013-28. [PMID: 30232239 DOI: 10.1042/CS20171110] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
338 Dionne S, Laberge S, Deslandres C, Seidman EG. Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease. Clin Exp Immunol 2003;133:108-14. [PMID: 12823284 DOI: 10.1046/j.1365-2249.2003.02191.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
339 Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:79-85. [PMID: 20134489 DOI: 10.1038/nrgastro.2009.220] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
340 Peloso PM, Braun J. Expanding the armamentarium for the spondyloarthropathies. Arthritis Res Ther. 2004;6 Suppl 2:S36-S43. [PMID: 15228620 DOI: 10.1186/ar1012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
341 Minderhoud IM, Samsom M, Oldenburg B. Crohn’s disease, fatigue, and infliximab: Is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007; 13(14): 2089-2093 [PMID: 17465453 DOI: 10.3748/wjg.v13.i14.2089] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 57] [Article Influence: 4.0] [Reference Citation Analysis]
342 Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol 2016;51:1062-8. [PMID: 27002981 DOI: 10.3109/00365521.2016.1149883] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
343 Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol 2016;152:164-72. [PMID: 26510126 DOI: 10.1001/jamadermatol.2015.3029] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 13.7] [Reference Citation Analysis]
344 Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci. 2004;49:1-4. [PMID: 14992426 DOI: 10.1023/b:ddas.0000011827.87103.2e] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
345 Namba T, Tanaka K, Ito Y, Ishihara T, Hoshino T, Gotoh T, Endo M, Sato K, Mizushima T. Positive role of CCAAT/enhancer-binding protein homologous protein, a transcription factor involved in the endoplasmic reticulum stress response in the development of colitis. Am J Pathol 2009;174:1786-98. [PMID: 19359519 DOI: 10.2353/ajpath.2009.080864] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 6.3] [Reference Citation Analysis]
346 Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 1999;58 Suppl 1:I61-4. [PMID: 10577975 DOI: 10.1136/ard.58.2008.i61] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 1.7] [Reference Citation Analysis]
347 Brown GR, Thiele DL. T-cell activation and differentiation are regulated by TNF during murine DBA/2-->B6D2F1 intestinal graft-versus-host disease. J Clin Immunol 2000;20:379-88. [PMID: 11051280 DOI: 10.1023/a:1006676315093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
348 Gwon Y, Mo M, Chen MH, Chi Z, Li J, Xia AH, Ibrahim JG. Network meta-regression for ordinal outcomes: Applications in comparing Crohn's disease treatments. Stat Med 2020. [PMID: 32166784 DOI: 10.1002/sim.8518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
349 Yu L, Yang X, Xia L, Zhong J, Ge W, Wu J, Liu H, Liu F, Liu Z. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm 2015;2015:793764. [PMID: 25873771 DOI: 10.1155/2015/793764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
350 Scherl EJ, Kumar S, Warren RU. Review of the safety and efficacy of ustekinumab. Therap Adv Gastroenterol 2010;3:321-8. [PMID: 21180612 DOI: 10.1177/1756283X10374216] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
351 Cao BL, Qasem A, Sharp RC, Abdelli LS, Naser SA. Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα). World J Gastroenterol 2018; 24(25): 2764-2775 [PMID: 29991880 DOI: 10.3748/wjg.v24.i25.2764] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
352 Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 2005;23:875-88. [PMID: 16153132 DOI: 10.2165/00019053-200523090-00002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
353 Wirtz S, Galle PR, Neurath MF. Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut. 1999;44:800-807. [PMID: 10323880 DOI: 10.1136/gut.44.6.800] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 1.7] [Reference Citation Analysis]
354 Carter CT, Waters HC, Smith DB. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's disease. Patient Prefer Adherence 2012;6:417-26. [PMID: 22723726 DOI: 10.2147/PPA.S31115] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
355 Kishimoto K, Nozaki Y, Sakurai T, Kinoshita K, Funauchi M, Matsumura I. Takayasu's Arteritis Diagnosed in an Adolescent Patient with Crohn's Disease: Management of Biologicals. Life (Basel) 2021;11:1019. [PMID: 34685390 DOI: 10.3390/life11101019] [Reference Citation Analysis]
356 Williams G, Khan AA, Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol 2005;16:289-92. [PMID: 18159561 DOI: 10.1155/2005/814698] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
357 Osterman MT, VanDussen KL, Gordon IO, Davis EM, Li K, Simpson K, Ciorba M, Glover SC, Abraham B, Guo X, Yee EU, Allard FD, Perrigoue JG, Claggett B, Shen B, Stappenbeck TS, Liu JJ. Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease. Inflamm Bowel Dis 2021;27:677-85. [PMID: 32964238 DOI: 10.1093/ibd/izaa251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
358 Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. [PMID: 15647188 DOI: 10.1136/gut.2004.045294] [Cited by in Crossref: 466] [Cited by in F6Publishing: 418] [Article Influence: 27.4] [Reference Citation Analysis]
359 Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33. [PMID: 10834859 DOI: 10.1136/ard.59.6.428] [Cited by in Crossref: 190] [Cited by in F6Publishing: 179] [Article Influence: 8.6] [Reference Citation Analysis]
360 Giuffrida P, Cococcia S, Delliponti M, Lenti MV, Di Sabatino A. Controlling Gut Inflammation by Restoring Anti-Inflammatory Pathways in Inflammatory Bowel Disease. Cells 2019;8:E397. [PMID: 31052214 DOI: 10.3390/cells8050397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
361 Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. CNS Drugs 2016;30:1111-20. [PMID: 27470609 DOI: 10.1007/s40263-016-0374-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 17.8] [Reference Citation Analysis]
362 Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007;117:289-296. [PMID: 17273548 DOI: 10.1172/jci30555] [Cited by in Crossref: 955] [Cited by in F6Publishing: 417] [Article Influence: 63.7] [Reference Citation Analysis]
363 Fan R, Zhong J, Wang ZT, Li SY, Zhou J, Tang YH. Evaluation of “top-down” treatment of early Crohn’s disease by double balloon enteroscopy. World J Gastroenterol 2014; 20(39): 14479-14487 [PMID: 25339835 DOI: 10.3748/wjg.v20.i39.14479] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
364 Facchini FA, Di Fusco D, Barresi S, Luraghi A, Minotti A, Granucci F, Monteleone G, Peri F, Monteleone I. Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis. Eur J Clin Pharmacol 2020;76:409-18. [PMID: 31982922 DOI: 10.1007/s00228-019-02799-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
365 Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol 2021;18:544-58. [PMID: 33712743 DOI: 10.1038/s41575-021-00424-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
366 Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, Gentilini L, Bazzi P, Rizzello F, Coscia M. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301-8. [PMID: 18360638 DOI: 10.2147/tcrm.2007.3.2.301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
367 Freeman K, Taylor-Phillips S, Connock M, Court R, Tsertsvadze A, Shyangdan D, Auguste P, Mistry H, Arasaradnam R, Sutcliffe P, Clarke A. Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis. BMJ Open 2017;7:e014581. [PMID: 28674134 DOI: 10.1136/bmjopen-2016-014581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
368 Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100:2610-2615. [PMID: 12604793 DOI: 10.1073/pnas.0337679100] [Cited by in Crossref: 1508] [Cited by in F6Publishing: 1394] [Article Influence: 79.4] [Reference Citation Analysis]
369 Singh M, Diwan MM, Patel KC. A rare case of supraventricular tachycardia induced by Infliximab: a case report. Cases J. 2009;2:147. [PMID: 19946518 DOI: 10.1186/1757-1626-2-147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
370 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
371 Krupa LZ, Kennedy HJ, Jamieson CP, Fisher N, Hart AR. The reasons for discontinuation of infliximab treatment in patients with Crohn's disease: a review of practice at NHS teaching hospital. ISRN Gastroenterol 2011;2011:672017. [PMID: 22111012 DOI: 10.5402/2011/672017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
372 Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg 2007;20:269-81. [PMID: 20011423 DOI: 10.1055/s-2007-991026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
373 Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology 2008;33:1305-12. [PMID: 18819754 DOI: 10.1016/j.psyneuen.2008.08.007] [Cited by in Crossref: 153] [Cited by in F6Publishing: 130] [Article Influence: 10.9] [Reference Citation Analysis]
374 Quaedvlieg V, Henket M, Sele J, Louis R. Cytokine production from sputum cells in eosinophilic versus non-eosinophilic asthmatics. Clin Exp Immunol 2006;143:161-6. [PMID: 16367947 DOI: 10.1111/j.1365-2249.2005.02968.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
375 Luck ME, Muljo SA, Collins CB. Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases. J Immunol. 2015;194:5047-5052. [PMID: 25980029 DOI: 10.4049/jimmunol.1403146] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
376 McNamee EN, Wermers JD, Masterson JC, Collins CB, Lebsack MD, Fillon S, Robinson ZD, Grenawalt J, Lee JJ, Jedlicka P, Furuta GT, Rivera-Nieves J. Novel model of TH2-polarized chronic ileitis: the SAMP1 mouse. Inflamm Bowel Dis 2010;16:743-52. [PMID: 19856411 DOI: 10.1002/ibd.21148] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
377 Kanai T, Totsuka T, Tezuka K, Watanabe M. ICOS costimulation in inflammatory bowel disease. J Gastroenterol 2002;37 Suppl 14:78-81. [PMID: 12572871 DOI: 10.1007/BF03326419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
378 Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:518-23. [PMID: 14602063 DOI: 10.1007/s11894-003-0043-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
379 Schmidt C, Giese T, Goebel R, Schilling M, Marth T, Ruether A, Schreiber S, Zeuzem S, Meuer SC, Stallmach A. Interleukin-18 is increased only in a minority of patients with active Crohn's disease. Int J Colorectal Dis. 2007;22:1013-1020. [PMID: 17318554 DOI: 10.1007/s00384-007-0282-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
380 Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut. 2005;54:890. [PMID: 15888806 DOI: 10.1136/gut.2005.065417] [Cited by in Crossref: 111] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
381 Kamel AY, Concepcion O, Schlachterman A, Glover S, Forsmark CY. Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease. ACG Case Rep J 2016;3:187-9. [PMID: 27144200 DOI: 10.14309/crj.2016.45] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
382 Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. [PMID: 17916445 DOI: 10.1016/j.clim.2007.08.012] [Cited by in Crossref: 156] [Cited by in F6Publishing: 149] [Article Influence: 10.4] [Reference Citation Analysis]
383 Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut. 2004;53:1556-1558. [PMID: 15479669 DOI: 10.1136/gut.2004.040824] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 2.3] [Reference Citation Analysis]
384 Schoultz I, Keita ÅV. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function. Cells 2019;8:E193. [PMID: 30813280 DOI: 10.3390/cells8020193] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
385 Conroy CA, Cattell R. Infliximab treatment for Crohn's disease. Postgrad Med J 2001;77:436-40. [PMID: 11423591 DOI: 10.1136/pmj.77.909.436] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
386 Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104:383-389. [PMID: 10449430 DOI: 10.1172/jci7145] [Cited by in Crossref: 574] [Cited by in F6Publishing: 167] [Article Influence: 25.0] [Reference Citation Analysis]
387 Kuek A, Hazleman BL, Ostör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-60. [PMID: 17403952 DOI: 10.1136/pgmj.2006.052688] [Cited by in Crossref: 166] [Cited by in F6Publishing: 154] [Article Influence: 11.1] [Reference Citation Analysis]
388 Wazea SA, Wadie W, Bahgat AK, El-Abhar HS. Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways. Sci Rep 2018;8:5110. [PMID: 29572553 DOI: 10.1038/s41598-018-23359-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
389 Stallmach A, Marth T, Weiss B, Wittig BM, Hombach A, Schmidt C, Neurath M, Zeitz M, Zeuzem S, Abken H. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo. Gut 2004;53:339-45. [PMID: 14960512 DOI: 10.1136/gut.2003.020107] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.4] [Reference Citation Analysis]
390 Bakirtzi K, Hoffman JM, Pothoulakis C. Silence Please!: siRNA approaches to tighten the intestinal barrier in vivo. Am J Pathol 2013;183:1700-2. [PMID: 24183845 DOI: 10.1016/j.ajpath.2013.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
391 Khan MA. Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis 2002;61 Suppl 3:iii3-7. [PMID: 12381505 DOI: 10.1136/ard.61.suppl_3.iii3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
392 Jatoi A, Jett JR, Sloan J, Novotny P, Ford J, Prabhakar U, Loprinzi CL. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer 2004;12:859-63. [PMID: 15372221 DOI: 10.1007/s00520-004-0638-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
393 Neyt M, Christiaens A, Aloi M, de Ridder L, Croft NM, Koletzko S, Levine A, Turner D, Russell RK, Ruemmele FM, Veereman G. Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment. JMIR Form Res 2021;5:e13888. [PMID: 33492239 DOI: 10.2196/13888] [Reference Citation Analysis]
394 Kullberg BJ, Ferwerda G, de Jong DJ, Drenth JP, Joosten LA, Van der Meer JW, Netea MG. Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology 2008;123:600-5. [PMID: 18028374 DOI: 10.1111/j.1365-2567.2007.02735.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
395 Sands BE. New biologic agents: a critical appraisal. Curr Gastroenterol Rep 1999;1:470-5. [PMID: 10980988 DOI: 10.1007/s11894-999-0005-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
396 Carter MJ, Lobo AJ, Travis SP; IBD Section; British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.043372] [Cited by in Crossref: 700] [Cited by in F6Publishing: 644] [Article Influence: 38.9] [Reference Citation Analysis]
397 Otley A, Critch J, Butzner JD. Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy. Paediatr Child Health 2004;9:87-9. [PMID: 19654986 DOI: 10.1093/pch/9.2.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
398 Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D; RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114. [PMID: 16859506 DOI: 10.1186/ar1994] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 5.8] [Reference Citation Analysis]
399 Buurman DJ, Blokzijl T, Festen EAM, Pham BT, Faber KN, Brouwer E, Dijkstra G. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar. PLoS One 2018;13:e0208922. [PMID: 30533022 DOI: 10.1371/journal.pone.0208922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
400 Kim KW, Kim HR. Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis. Korean J Intern Med 2016;31:634-42. [PMID: 27169879 DOI: 10.3904/kjim.2016.098] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
401 Ohkawara T, Miyashita K, Nishihira J, Mitsuyama K, Takeda H, Kato M, Kondo N, Yamasaki Y, Sata M, Yoshiki T. Transgenic over-expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol. 2005;140:241-248. [PMID: 15807847 DOI: 10.1111/j.1365-2249.2005.02771.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
402 Mencel M, Nash M, Jacobson C. Neuregulin upregulates microglial α7 nicotinic acetylcholine receptor expression in immortalized cell lines: implications for regulating neuroinflammation. PLoS One 2013;8:e70338. [PMID: 23936190 DOI: 10.1371/journal.pone.0070338] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
403 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
404 Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur J Gastroenterol Hepatol. 2007;19:217-223. [PMID: 17301648 DOI: 10.1097/01.meg.0000250590.84102.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
405 Mukhtyar C, Chan A, Luqmani R. Update on the use of biologics in primary systemic vasculitides. Expert Rev Clin Immunol 2007;3:901-11. [PMID: 20477139 DOI: 10.1586/1744666X.3.6.901] [Reference Citation Analysis]
406 Yan Y, Dalmasso G, Nguyen HT, Obertone TS, Charrier-Hisamuddin L, Sitaraman SV, Merlin D. Nuclear factor-kappaB is a critical mediator of Ste20-like proline-/alanine-rich kinase regulation in intestinal inflammation. Am J Pathol 2008;173:1013-28. [PMID: 18787102 DOI: 10.2353/ajpath.2008.080339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
407 Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. [PMID: 15647188 DOI: 10.1136/gut.2004.04294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
408 Ito H, Hirotani T, Yamamoto M, Ogawa H, Kishimoto T. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J Gastroenterol 2002;37 Suppl 14:56-61. [PMID: 12572867 DOI: 10.1007/BF03326415] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
409 Belmiro CL, Castelo-Branco MT, Melim LM, Schanaider A, Elia C, Madi K, Pavão MS, de Souza HS. Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem 2009;284:11267-78. [PMID: 19258310 DOI: 10.1074/jbc.M807211200] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
410 Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. World J Gastrointest Pharmacol Ther 2017; 8(2): 131-136 [PMID: 28533923 DOI: 10.4292/wjgpt.v8.i2.131] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
411 Kuhbacher T, Fölsch U. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007; 13(8): 1149-1155 [PMID: 17451192 DOI: 10.3748/wjg.v13.i8.1149] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
412 Alters SE, McLaughlin B, Spink B, Lachinyan T, Wang CW, Podust V, Schellenberger V, Stemmer WP. GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. PLoS One 2012;7:e50630. [PMID: 23189208 DOI: 10.1371/journal.pone.0050630] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
413 Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm 2014;2014:172821. [PMID: 24757282 DOI: 10.1155/2014/172821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
414 Menegatti S, Bianchi E, Rogge L. Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. Front Immunol 2019;10:382. [PMID: 30941119 DOI: 10.3389/fimmu.2019.00382] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
415 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
416 Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT, Cominelli F. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA. 2003;100:8366-8371. [PMID: 12832622 DOI: 10.1073/pnas.1432897100] [Cited by in Crossref: 146] [Cited by in F6Publishing: 148] [Article Influence: 7.7] [Reference Citation Analysis]
417 Tsoukka M, Jelastopulu E, Lavranos G, Charalambous G. Estimation of quality of life in Cypriot patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(1): 121-126 [PMID: 28104987 DOI: 10.3748/wjg.v23.i1.121] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
418 Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellström PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders. World J Gastroenterol 2006; 12(21): 3386-3392 [PMID: 16733856 DOI: 10.3748/wjg.v12.i21.3386] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
419 Huang YH, Magleby R, Rao R, Walsh TJ, Singh HK. Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy. Med Mycol Case Rep 2021;32:43-6. [PMID: 33816098 DOI: 10.1016/j.mmcr.2021.03.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
420 Clark-Snustad KD, Singla A, Lee SD. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists. Dig Dis Sci 2019;64:1952-8. [PMID: 30815825 DOI: 10.1007/s10620-019-05490-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
421 Moroi R, Endo K, Kinouchi Y, Shiga H, Kakuta Y, Kuroha M, Kanazawa Y, Shimodaira Y, Horiuchi T, Takahashi S. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity. Immunogenetics. 2013;65:265-271. [PMID: 23358932 DOI: 10.1007/s00251-013-0679-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
422 Guo Y, Lu N, Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int. 2013;2013:581631. [PMID: 23484133 DOI: 10.1155/2013/581631] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
423 Hobbs SS, Goettel JA, Liang D, Yan F, Edelblum KL, Frey MR, Mullane MT, Polk DB. TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G220-G229. [PMID: 21566012 DOI: 10.1152/ajpgi.00383.2010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
424 Berkovitch G, Cohen S, Lubetzky R, Singer D, Yerushalmy-Feler A. Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD. BMC Pediatr 2021;21:63. [PMID: 33541320 DOI: 10.1186/s12887-021-02526-1] [Reference Citation Analysis]
425 Abreu MT. DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD. Dig Dis Sci 2019;64:3377-81. [PMID: 31628571 DOI: 10.1007/s10620-019-05796-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
426 Ohkawara T, Takeda H, Nishihira J, Miyashita K, Nihiwaki M, Ishiguro Y, Takeda K, Akira S, Iwanaga T, Sugiyama T. Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice. Clin Exp Immunol. 2005;141:412-421. [PMID: 16045730 DOI: 10.1111/j.1365-2249.2005.02877.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
427 Yada S, Matsumoto T, Esaki M, Jo Y, Koga H, Nakamura S, Iida M. Differential expression of leukocyte functions associated antigen-1 (LFA-1) on peripheral blood mononuclear cells in patients with Crohn's disease. Inflamm Bowel Dis 2009;15:1379-84. [PMID: 19340879 DOI: 10.1002/ibd.20935] [Reference Citation Analysis]
428 Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 2002;61 Suppl 3:iii51-60. [PMID: 12381511 DOI: 10.1136/ard.61.suppl_3.iii51] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
429 Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79-94. [PMID: 11781268 DOI: 10.1128/cmr.15.1.79-94.2002] [Cited by in Crossref: 302] [Cited by in F6Publishing: 121] [Article Influence: 15.1] [Reference Citation Analysis]
430 Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2007;1:89-100. [PMID: 19072438 DOI: 10.1586/17474124.1.1.89] [Reference Citation Analysis]
431 Simon EG, Ghosh S, Iacucci M, Moran GW. Ustekinumab for the treatment of Crohn's disease: can it find its niche? Therap Adv Gastroenterol 2016;9:26-36. [PMID: 26770265 DOI: 10.1177/1756283X15618130] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
432 Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007;67:2511-37. [PMID: 18034589 DOI: 10.2165/00003495-200767170-00005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
433 Schroeder S, Atkins D, Furuta GT. Recent advances in the treatment of eosinophilic esophagitis. Expert Rev Clin Immunol 2010;6:929-37. [PMID: 20979557 DOI: 10.1586/eci.10.65] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
434 Miyoshi J, Sofia MA, Pierre JF. The evidence for fungus in Crohn's disease pathogenesis. Clin J Gastroenterol 2018;11:449-56. [PMID: 30027368 DOI: 10.1007/s12328-018-0886-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
435 Sou S, Matsui T, Yao T, Naito M, Yorioka M, Beppu T, Nagahama T, Futami K. Differentiating enterocutaneous fistulae from suture abscesses complicating Crohn's disease using oral administration of indocyanine green. J Gastroenterol Hepatol 2006;21:1850-3. [PMID: 17074025 DOI: 10.1111/j.1440-1746.2006.04287.x] [Reference Citation Analysis]
436 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
437 Hansson-Hedblom A, Almond C, Borgström F, Sly I, Enkusson D, Troelsgaard Buchholt A, Karlsson L. Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden. Cost Eff Resour Alloc 2018;16:28. [PMID: 30123097 DOI: 10.1186/s12962-018-0114-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
438 Majidova K, Handfield J, Kafi K, Martin RD, Kubinski R. Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review. Genes (Basel) 2021;12:1465. [PMID: 34680860 DOI: 10.3390/genes12101465] [Reference Citation Analysis]
439 Whittall T, Wang Y, Kelly CG, Thompson R, Sanderson J, Lomer M, Soon SY, Bergmeier LA, Singh M, Lehner T. Tumour necrosis factor-alpha production stimulated by heat shock protein 70 and its inhibition in circulating dendritic cells and cells eluted from mucosal tissues in Crohn's disease. Clin Exp Immunol. 2006;143:550-559. [PMID: 16487255 DOI: 10.1111/j.1365-2249.2006.03010.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
440 Lee JS, Park SY, Thapa D, Choi MK, Chung IM, Park YJ, Yong CS, Choi HG, Kim JA. Grifola frondosa water extract alleviates intestinal inflammation by suppressing TNF-alpha production and its signaling. Exp Mol Med 2010;42:143-54. [PMID: 20054232 DOI: 10.3858/emm.2010.42.2.016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
441 Carvalho AT, Souza H, Carneiro AJ, Castelo-Branco M, Madi K, Schanaider A, Silva F, Pereira Jứnior FA, Pereira MG, Tortori C, Dines I, Carvalho J, Rocha E, Elia C. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-α, IL-12 and VEGF production. World J Gastroenterol 2007; 13(15): 2166-2173 [PMID: 17465495 DOI: 10.3748/wjg.v13.i15.2166] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
442 Qazi T, Shah B, El-Dib M, Farraye FA. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2016;61:589-96. [PMID: 26441281 DOI: 10.1007/s10620-015-3893-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
443 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
444 Odashima M, Otaka M, Jin M, Horikawa Y, Matsuhashi T, Ohba R, Koizumi S, Kinoshita N, Takahashi T, Watanabe S. Successful treatment of refractory duodenal Crohn's disease with infliximab. Dig Dis Sci 2007;52:31-2. [PMID: 17171444 DOI: 10.1007/s10620-006-9585-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
445 Nagata Y, Esaki M, Moriyama T, Hirano A, Umeno J, Maehata Y, Torisu T, Matsumoto T, Kitazono T. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type. J Gastroenterol 2019;54:330-8. [PMID: 30244398 DOI: 10.1007/s00535-018-1511-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
446 Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Ozaki K, Watanabe M, Hibi T. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 2016;51:241-251. [PMID: 26162647 DOI: 10.1007/s00535-015-1102-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
447 Guo C, Shen J. Cytoskeletal Organization and Cell Polarity in the Pathogenesis of Crohn’s Disease. Clinic Rev Allerg Immunol 2021;60:164-74. [DOI: 10.1007/s12016-020-08795-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
448 Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43:603-617. [PMID: 25110261 DOI: 10.1016/j.gtc.2014.05.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
449 Odes S, Greenberg D. A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res 2014;6:431-43. [PMID: 25336980 DOI: 10.2147/CEOR.S39212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
450 Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med. 2002;195:1129-1143. [PMID: 11994418 DOI: 10.1084/jem.20011956] [Cited by in Crossref: 433] [Cited by in F6Publishing: 434] [Article Influence: 21.7] [Reference Citation Analysis]
451 Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66-82. [PMID: 25729432 DOI: 10.1177/1756283x14558193] [Cited by in Crossref: 89] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
452 White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. Drugs 2006;66:1209-28. [PMID: 16827598 DOI: 10.2165/00003495-200666090-00004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
453 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
454 Caprioli F, Caruso R, Sarra M, Pallone F, Monteleone G. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol 2012;165:820-8. [PMID: 21806600 DOI: 10.1111/j.1476-5381.2011.01614.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
455 Zemljic M, Pejkovic B, Krajnc I, Lipovsek S. Biological pathways involved in the development of inflammatory bowel disease. Wien Klin Wochenschr. 2014;126:626-633. [PMID: 25256178 DOI: 10.1007/s00508-014-0592-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
456 Poritz LS, Gagliano GA, McLeod RS, MacRae H, Cohen Z. Surgical management of entero and colocutaneous fistulae in Crohn's disease: 17 year's experience. Int J Colorectal Dis 2004;19:481-5; discussion 486. [PMID: 15168043 DOI: 10.1007/s00384-004-0580-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
457 Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12. [PMID: 11830424 DOI: 10.1136/ard.61.3.207] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 3.6] [Reference Citation Analysis]
458 Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004;53:780-2. [PMID: 15138201 DOI: 10.1136/gut.2003.020552] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
459 Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr Treat Options Gastro 2007;10:185-94. [DOI: 10.1007/s11938-007-0012-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
460 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
461 Greenwald DA, Brandt LJ. Inflammatory Bowel Disease After Age 60. Curr Treat Options Gastroenterol. 2003;6:213-225. [PMID: 12744821 DOI: 10.1007/s11938-003-0003-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
462 Punit S, Dubé PE, Liu CY, Girish N, Washington MK, Polk DB. Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis. Gastroenterology 2015;149:993-1005.e2. [PMID: 26072395 DOI: 10.1053/j.gastro.2015.06.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
463 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
464 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
465 Puigventós Latorre F. Novedades terapéuticas del año 2000: los retos del médico y del gestor. Medicina Clínica 2001;116:465-8. [DOI: 10.1016/s0025-7753(01)71871-4] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
466 Padua D, Vu JP, Germano PM, Pisegna JR. The Role of Neuropeptides in Mouse Models of Colitis. J Mol Neurosci. 2016;59:203-210. [PMID: 26646243 DOI: 10.1007/s12031-015-0688-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
467 Baldauf KJ, Royal JM, Kouokam JC, Haribabu B, Jala VR, Yaddanapudi K, Hamorsky KT, Dryden GW, Matoba N. Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon. Mucosal Immunol 2017;10:887-900. [PMID: 27805617 DOI: 10.1038/mi.2016.95] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
468 Imam T, Park S, Kaplan MH, Olson MR. Effector T Helper Cell Subsets in Inflammatory Bowel Diseases. Front Immunol 2018;9:1212. [PMID: 29910812 DOI: 10.3389/fimmu.2018.01212] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 19.0] [Reference Citation Analysis]
469 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
470 Shukla T, Sands BE. Novel Non-biologic Targets for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0689-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
471 Hsieh CY, Osaka T, Moriyama E, Date Y, Kikuchi J, Tsuneda S. Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum. Physiol Rep 2015;3:e12327. [PMID: 25780093 DOI: 10.14814/phy2.12327] [Cited by in Crossref: 96] [Cited by in F6Publishing: 84] [Article Influence: 13.7] [Reference Citation Analysis]
472 Akobeng AK. Evidence in practice. Arch Dis Child 2005;90:849-52. [PMID: 16040887 DOI: 10.1136/adc.2004.058248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
473 Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63:1664-1669. [PMID: 15297279 DOI: 10.1136/ard.2003.012450] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 5.0] [Reference Citation Analysis]
474 Holko P, Kawalec P, Pilc A. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. Pharmacoeconomics 2018;36:853-65. [PMID: 29667146 DOI: 10.1007/s40273-018-0653-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
475 Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 5.1] [Reference Citation Analysis]
476 Dou Y, Li C, Li L, Guo J, Zhang J. Bioresponsive drug delivery systems for the treatment of inflammatory diseases. J Control Release 2020;327:641-66. [PMID: 32911014 DOI: 10.1016/j.jconrel.2020.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
477 Azer SA, Azer S. Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open 2016;6:e009889. [PMID: 26857105 DOI: 10.1136/bmjopen-2015-009889] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
478 Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut. 2000;47:57-62. [PMID: 10861265 DOI: 10.1136/gut.47.1.57] [Cited by in Crossref: 96] [Cited by in F6Publishing: 105] [Article Influence: 4.4] [Reference Citation Analysis]
479 D'Haens G, Daperno M. Advances in medical therapy for Crohn's disease. Curr Gastroenterol Rep 2002;4:506-12. [PMID: 12441041 DOI: 10.1007/s11894-002-0027-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
480 Das KM, Farag SA. Current medical therapy of inflammatory bowel disease. World J Gastroenterol 2000; 6(4): 483-489 [PMID: 11819634 DOI: 10.3748/wjg.v6.i4.483] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
481 Collins CB, Aherne CM, Ehrentraut SF, Gerich ME, McNamee EN, McManus MC, Lebsack MD, Jedlicka P, Azam T, de Zoeten EF. Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis. Inflamm Bowel Dis. 2013;19:1964-1973. [PMID: 23835442 DOI: 10.1097/mib.0b013e31829292aa] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
482 Kim NH, Jung YS, Moon CM, Lee SY, Kim ER, Kim YH, Lee CK, Lee SH, Kim JH, Huh KC, Yoon SM, Song HJ, Boo SJ, Jang HJ, Kim YS, Lee KM, Shin JE, Park DI. Long-term clinical outcomes of korean patient with Crohn's disease following early use of infliximab. Intest Res 2014;12:281-6. [PMID: 25374493 DOI: 10.5217/ir.2014.12.4.281] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
483 Gouldthorpe O, Catto-Smith AG, Alex G. Biologics in paediatric Crohn's disease. Gastroenterol Res Pract 2011;2011:287574. [PMID: 22144993 DOI: 10.1155/2011/287574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
484 Scott FI, Osterman MT. Medical management of crohn disease. Clin Colon Rectal Surg 2013;26:67-74. [PMID: 24436652 DOI: 10.1055/s-0033-1348043] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
485 Wei F, Zhang Y, Jian J, Mundra JJ, Tian Q, Lin J, Lafaille JJ, Tang W, Zhao W, Yu X, Liu CJ. PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner. Sci Rep 2014;4:7023. [PMID: 25387791 DOI: 10.1038/srep07023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
486 van Deventer SJ. Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis 1999;58 Suppl 1:I114-20. [PMID: 10577987 DOI: 10.1136/ard.58.2008.i114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
487 Sumi R, Nakajima K, Iijima H, Wasa M, Shinzaki S, Nezu R, Inoue Y, Ito T. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease. Surg Today. 2016;46:922-929. [PMID: 26438200 DOI: 10.1007/s00595-015-1257-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
488 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Watanabe K, Ito M, Komatsu M, Sugawara T. Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial. Perm J 2017;21:17-009. [PMID: 29035182 DOI: 10.7812/TPP/17-009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
489 Badgett MJ, Mize E, Fletcher T, Boyes B, Orlando R. Predicting the HILIC Retention Behavior of the N-Linked Glycopeptides Produced by Trypsin Digestion of Immunoglobulin Gs (IgGs). J Biomol Tech 2018;29:98-104. [PMID: 30479582 DOI: 10.7171/jbt.18-2904-002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
490 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Reference Citation Analysis]
491 van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, Dijkmans BA, Tak PP, Verweij CL. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010;12:R11. [PMID: 20096109 DOI: 10.1186/ar2912] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
492 Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2019;. [PMID: 31196874 DOI: 10.1136/gutjnl-2019-318440] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 18.3] [Reference Citation Analysis]
493 Zeitz J, Huber M, Rogler G. [Serious course of a miliary tuberculosis in a 34-year-old patient with ulcerative colitis and HIV infection under concomitant therapy with infliximab]. Med Klin (Munich) 2010;105:314-8. [PMID: 20455057 DOI: 10.1007/s00063-010-1046-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
494 Mielants H, De Keyser F, Baeten D, Van den Bosch F. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep 2005;7:188-94. [PMID: 15918994 DOI: 10.1007/s11926-996-0038-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
495 Eysselein VE. Proteolytic release of membrane bound intercellular regulators. Gut 1999;44:454. [PMID: 10075948 DOI: 10.1136/gut.44.4.454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
496 Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol. 2003;133:38-43. [PMID: 12823276 DOI: 10.1046/j.1365-2249.2003.02193.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 3.9] [Reference Citation Analysis]
497 Ishida K, Inoue T, Fujiwara K, Sakanaka T, Narabayashi K, Nouda S, Okada T, Kakimoto K, Kuramoto T, Kawakami K, Abe Y, Takeuchi T, Murano M, Tokioka S, Umegaki E, Higuchi K. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol 2013; 19(17): 2676-2682 [PMID: 23674875 DOI: 10.3748/wjg.v19.i17.2676] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
498 Aceituno M, Panés J. Patogenia e inmunoterapia de la enfermedad inflamatoria intestinal: lecciones de los modelos animales. Gastroenterología y Hepatología 2005;28:576-90. [DOI: 10.1157/13080611] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
499 French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity Associated with the Use of Anti-TNF-α Agents. Drug Saf 2016;39:199-208. [PMID: 26692395 DOI: 10.1007/s40264-015-0366-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
500 Dubé PE, Punit S, Polk DB. Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2015;308:G161-70. [PMID: 25477373 DOI: 10.1152/ajpgi.00142.2014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
501 Stio M, Treves C, Martinesi M, d’Albasio G, Bagnoli S, Bonanomi AG. Effect of anti-TNF therapy and vitamin D derivatives on the proliferation of peripheral blood mononuclear cells in Crohn’s disease. Dig Dis Sci. 2004;49:328-335. [PMID: 15104379 DOI: 10.1023/b:ddas.0000017460.90887.11] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
502 Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S, Toda A, Eyanagi R, Soeda S. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology 2007;122:54-64. [PMID: 17451462 DOI: 10.1111/j.1365-2567.2007.02612.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
503 Yarur AJ, Jain A, Quintero MA, Czul F, Deshpande AR, Kerman DH, Abreu MT. Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy. J Clin Gastroenterol 2019;53:210-5. [PMID: 29517712 DOI: 10.1097/MCG.0000000000001002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
504 Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: Need for HBV-screening? World J Gastroenterol 2006; 12(6): 974-976 [PMID: 16521231 DOI: 10.3748/wjg.v12.i6.974] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 99] [Article Influence: 6.6] [Reference Citation Analysis]
505 Mak WY, Segal JP, Hart A. Twenty years of biological therapy in an patient with IBD. BMJ Case Rep 2018;2018:bcr-2017-221994. [PMID: 29367361 DOI: 10.1136/bcr-2017-221994] [Reference Citation Analysis]
506 Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. [PMID: 17655372 DOI: 10.2165/00003088-200746080-00002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 11.1] [Reference Citation Analysis]
507 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(6): 1441-1444 [DOI: 10.11569/wcjd.v12.i6.1441] [Reference Citation Analysis]
508 Patel S, Needleman KIM. Funding Grants for Rare Diseases at the Food and Drug Administration. Expert Opinion on Orphan Drugs 2012. [DOI: 10.1080/21678707.2013.749181] [Reference Citation Analysis]
509 Rampton DS. Management of difficult inflammatory bowel disease: where are we now? World J Gastroenterol 2000; 6(3): 315-323 [PMID: 11819588 DOI: 10.3748/wjg.v6.i3.315] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
510 Carrington EM, Louis C, Kratina T, Hancock M, Keenan CR, Iannarella N, Allan RS, Wardak AZ, Czabotar PE, Herold MJ, Schenk RL, White CA, D'Silva D, Yang Y, Wong W, Wong H, Bryant VL, Huntington ND, Rautela J, Sutherland RM, Zhan Y, Hansen J, Nhu D, Lessene G, Wicks IP, Lew AM. BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia. Blood Adv 2021;5:2550-62. [PMID: 34100903 DOI: 10.1182/bloodadvances.2020004139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
511 Atreya R, Neumann H, Neurath MF. [Rational treatment of Crohn's disease]. MMW Fortschr Med 2013;155:61-3. [PMID: 23614201 DOI: 10.1007/s15006-013-0230-8] [Reference Citation Analysis]
512 Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1715-1735. [PMID: 18523998 DOI: 10.1002/ibd.20501] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
513 Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn WJ. Infliximab for Crohn’s disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013;58:797-806. [PMID: 23053885 DOI: 10.1007/s10620-012-2405-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
514 Ikeda R, Vermeulen LC, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar JM. Stability of infliximab in polyvinyl chloride bags. Am J Health Syst Pharm 2012;69:1509-12. [PMID: 22899746 DOI: 10.2146/ajhp100116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
515 Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs. 2006;66:1431-1439. [PMID: 16906776 DOI: 10.2165/00003495-200666110-00002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
516 Tan G, Li RH, Li C, Wu F, Zhao XM, Ma JY, Lei S, Zhang WD, Zhi FC. Down-regulation of human enteric antimicrobial peptides by NOD2 during differentiation of the paneth cell lineage. Sci Rep 2015;5:8383. [PMID: 25670499 DOI: 10.1038/srep08383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
517 Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, Stewart CA, Janelsins BM, Datta SK, Shen W, McLean MH. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology. 2014;146:210-221.e13. [PMID: 24120477 DOI: 10.1053/j.gastro.2013.09.060] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 9.8] [Reference Citation Analysis]
518 Shey MS, Garrett NJ, McKinnon LR, Passmore JA. The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene? Innate Immun 2015;21:99-112. [PMID: 24282122 DOI: 10.1177/1753425913513815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
519 MacManus CF, Collins CB, Nguyen TT, Alfano RW, Jedlicka P, de Zoeten EF. VEN-120, a Recombinant Human Lactoferrin, Promotes a Regulatory T Cell [Treg] Phenotype and Drives Resolution of Inflammation in Distinct Murine Models of Inflammatory Bowel Disease. J Crohns Colitis. 2017;11:1101-1112. [PMID: 28472424 DOI: 10.1093/ecco-jcc/jjx056] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
520 González-Amaro R, Díaz-González F, Sánchez-Madrid F. Adhesion molecules in inflammatory diseases. Drugs 1998;56:977-88. [PMID: 9878987 DOI: 10.2165/00003495-199856060-00003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 2.5] [Reference Citation Analysis]
521 Al Sulais E, AlAmeel T. Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease. Biologics 2020;14:1-11. [PMID: 32021084 DOI: 10.2147/BTT.S236433] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
522 Parhar K, Ray A, Steinbrecher U, Nelson C, Salh B. The p38 mitogen-activated protein kinase regulates interleukin-1beta-induced IL-8 expression via an effect on the IL-8 promoter in intestinal epithelial cells. Immunology. 2003;108:502-512. [PMID: 12667212 DOI: 10.1046/i.1365-2567.2003.01603.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
523 Pagnini C, Cominelli F. Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. Int J Mol Sci 2021;22:10273. [PMID: 34638616 DOI: 10.3390/ijms221910273] [Reference Citation Analysis]
524 Panés J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol. 1999;126:537-550. [PMID: 10188959 DOI: 10.1038/sj.bjp.0702328] [Cited by in Crossref: 172] [Cited by in F6Publishing: 159] [Article Influence: 7.5] [Reference Citation Analysis]
525 Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018;11:215-26. [PMID: 29844695 DOI: 10.2147/JIR.S165330] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
526 Kim YL, Park YS, Park EK, Park DR, Choi GS, Ahn SB, Kim SH, Jo YJ. Refractory duodenal Crohn's disease successfully treated with infliximab. Intest Res 2014;12:66-9. [PMID: 25349566 DOI: 10.5217/ir.2014.12.1.66] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
527 Frostberg E, Ström P, Gerke O, Qvist N. Infliximab's influence on anastomotic strength and degree of inflammation in intestinal surgery in a rabbit model. BMC Surg 2014;14:23. [PMID: 24762063 DOI: 10.1186/1471-2482-14-23] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
528 Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014;16:22-6. [PMID: 24114449 DOI: 10.1208/s12248-013-9534-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
529 Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429-448. [PMID: 11085348 DOI: 10.2165/00002018-200023050-00006] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 6.3] [Reference Citation Analysis]
530 Mesko B, Poliska S, Váncsa A, Szekanecz Z, Palatka K, Hollo Z, Horvath A, Steiner L, Zahuczky G, Podani J, Nagy AL. Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med 2013;5:59. [PMID: 23809696 DOI: 10.1186/gm463] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
531 Cominelli F, Arseneau KO, Rodriguez-Palacios A, Pizarro TT. Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model? Cell Mol Gastroenterol Hepatol. 2017;4:19-32. [PMID: 28560286 DOI: 10.1016/j.jcmgh.2017.02.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
532 Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145. [PMID: 12697733 DOI: 10.1172/jci16432] [Cited by in Crossref: 487] [Cited by in F6Publishing: 196] [Article Influence: 25.6] [Reference Citation Analysis]
533 Hou Q, Huang J, Ayansola H, Masatoshi H, Zhang B. Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. Front Immunol 2020;11:623691. [PMID: 33584726 DOI: 10.3389/fimmu.2020.623691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
534 McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4:883-898. [PMID: 23046232 DOI: 10.2217/imt.12.85] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
535 Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut. 1999;44:643-652. [PMID: 10205200 DOI: 10.1136/gut.44.5.643] [Cited by in Crossref: 106] [Cited by in F6Publishing: 106] [Article Influence: 4.6] [Reference Citation Analysis]
536 Stokkers PC, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:201-10. [PMID: 16901384 DOI: 10.1007/s11938-006-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
537 Garside P. Cytokines in experimental colitis. Clin Exp Immunol 1999;118:337-9. [PMID: 10594548 DOI: 10.1046/j.1365-2249.1999.01088.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 2.6] [Reference Citation Analysis]
538 Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, Zundler S, Rath T, Krebs S, Dörje F, Uter W, Nagore D, Meyer S, Neurath MF, Atreya R. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therap Adv Gastroenterol 2021;14:1756284820982802. [PMID: 33505519 DOI: 10.1177/1756284820982802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
539 Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008;1:23-30. [PMID: 19079157 DOI: 10.1038/mi.2007.1] [Cited by in Crossref: 326] [Cited by in F6Publishing: 297] [Article Influence: 25.1] [Reference Citation Analysis]
540 Borruel N, Carol M, Casellas F, Antolin M, de Lara F, Espin E, Naval J, Guarner F, Malagelada JR. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut. 2002;51:659-664. [PMID: 12377803 DOI: 10.1136/gut.51.5.659] [Cited by in Crossref: 216] [Cited by in F6Publishing: 201] [Article Influence: 10.8] [Reference Citation Analysis]
541 Shayowitz M, Bressler M, Ricardo AP, Grudnikoff E. Infliximab-induced Depression and Suicidal Behavior in Adolescent with Crohn's Disease: Case Report and Review of Literature. Pediatr Qual Saf 2019;4:e229. [PMID: 32010855 DOI: 10.1097/pq9.0000000000000229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
542 Ward MG, Irving PM, Sparrow MP. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11331-11342 [PMID: 26525434 DOI: 10.3748/wjg.v21.i40.11331] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
543 de Aguiar CF, Castoldi A, Andrade-Oliveira V, Ignacio A, da Cunha FF, Felizardo RJF, Bassi ÊJ, Câmara NOS, de Almeida DC. Mesenchymal stromal cells modulate gut inflammation in experimental colitis. Inflammopharmacology 2018;26:251-60. [PMID: 29063489 DOI: 10.1007/s10787-017-0404-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
544 Baik SH, Kim WH. A comprehensive review of inflammatory bowel disease focusing on surgical management. J Korean Soc Coloproctol 2012;28:121-31. [PMID: 22816055 DOI: 10.3393/jksc.2012.28.3.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
545 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
546 Zeisler B, Hyams JS. Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab. Pediatric Health Med Ther 2015;6:33-40. [PMID: 29388607 DOI: 10.2147/PHMT.S40948] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
547 Kirkegaard T, Pedersen G, Saermark T, Brynskov J. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol 2004;135:146-53. [PMID: 14678276 DOI: 10.1111/j.1365-2249.2004.02348.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
548 Webster JD, Vucic D. The Balance of TNF Mediated Pathways Regulates Inflammatory Cell Death Signaling in Healthy and Diseased Tissues. Front Cell Dev Biol 2020;8:365. [PMID: 32671059 DOI: 10.3389/fcell.2020.00365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
549 Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis 2002;61:960-7. [PMID: 12379516 DOI: 10.1136/ard.61.11.960] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
550 Collins CB, Aherne CM, Kominsky D, McNamee EN, Lebsack MD, Eltzschig H, Jedlicka P, Rivera-Nieves J. Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. Gastroenterology 2011;141:1821-31. [PMID: 22027263 DOI: 10.1053/j.gastro.2011.05.049] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
551 Chang MI, Cohen BL, Greenstein AJ. A review of the impact of biologics on surgical complications in Crohn's disease. Inflamm Bowel Dis 2015;21:1472-7. [PMID: 25811432 DOI: 10.1097/MIB.0000000000000362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
552 Wang L, Bai AP. Biological therapies for inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2010; 18(2): 107-112 [DOI: 10.11569/wcjd.v18.i2.107] [Reference Citation Analysis]
553 Kapila N, Gonzalez A, Rosado JM, Flocco G, Salomon F, Abusaif M, Hussain I, Moor MA, Modaresi-Esfeh J, Castro FJ. Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study. Therap Adv Gastroenterol 2021;14:17562848211037094. [PMID: 34707687 DOI: 10.1177/17562848211037094] [Reference Citation Analysis]
554 Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol. 2008;43:397-401. [PMID: 18592158 DOI: 10.1007/s00535-008-2165-x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
555 Tuskey A, Behm BW. Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease. Clin Exp Gastroenterol. 2014;7:173-179. [PMID: 24904220 DOI: 10.2147/ceg.s39518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
556 Taborda NA, Correa LA, Feria MG, Rugeles MT. The Spontaneous Control of HIV Replication is Characterized by Decreased Pathological Changes in the Gut-associated Lymphoid Tissue. Curr HIV Res 2018;16:338-44. [PMID: 30706820 DOI: 10.2174/1570162X17666190130115113] [Reference Citation Analysis]
557 Kato K, Fukunaga K, Kamikozuru K, Kashiwamura S, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Yokoyama Y, Kikuyama R, Miwa H, Matsumoto T. Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn's disease. Gut Liver 2011;5:37-45. [PMID: 21461070 DOI: 10.5009/gnl.2011.5.1.37] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
558 Chu CQ. Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases. Chin Med J (Engl) 2021;134:2525-8. [PMID: 34670251 DOI: 10.1097/CM9.0000000000001846] [Reference Citation Analysis]
559 Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med 2016;12:1693-704. [PMID: 27588089 DOI: 10.3892/etm.2016.3548] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
560 Wirtz S, Neurath MF. Illuminating the role of type I IFNs in colitis. J Clin Invest 2005;115:586-8. [PMID: 15765141 DOI: 10.1172/JCI24518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
561 Mohamed R, Schultz R, Fedorak RN. Oropharyngeal Crohn's disease. Clin Exp Gastroenterol 2008;1:15-8. [PMID: 21677821 DOI: 10.2147/ceg.s3755] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
562 Colman RJ, Portocarrero-Castillo A, Chona D, Hellmann J, Minar P, Rosen MJ. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflamm Bowel Dis 2021;27:507-15. [PMID: 32426829 DOI: 10.1093/ibd/izaa108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
563 Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut. 2007;56:509-517. [PMID: 17082252 DOI: 10.1136/gut.2006.105379] [Cited by in Crossref: 118] [Cited by in F6Publishing: 115] [Article Influence: 7.4] [Reference Citation Analysis]
564 Zwiers A, Bouma G. Recent advances in the etiology and treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2006;2:245-56. [PMID: 20477075 DOI: 10.1586/1744666X.2.2.245] [Reference Citation Analysis]
565 Edwards SJ, Barton S, Bacelar M, Karner C, Cain P, Wakefield V, Marceniuk G. Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study. Health Technol Assess 2021;25:1-138. [PMID: 33783345 DOI: 10.3310/hta25230] [Reference Citation Analysis]
566 Alnaimat F, Sidhu P, Sarkar S. T-cell targeted therapies in autoimmune diseases. Drug Dev Res 2011;72:585-97. [DOI: 10.1002/ddr.20468] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
567 Van den Bosch F, Baeten D, Kruithof E, De Keyser F, Mielants H, Veys EM. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis 2001;60 Suppl 3:iii33-6. [PMID: 11890649 DOI: 10.1136/ard.60.90003.iii33] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
568 Lee JS, Lee JH, Lee JH, Lee HJ, Kim MJ, Lee HJ, Choe YH. Efficacy of early treatment with infliximab in pediatric Crohn’s disease. World J Gastroenterol 2010; 16(14): 1776-1781 [PMID: 20380012 DOI: 10.3748/wjg.v16.i14.1776] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
569 Rahman FZ, Takhar GK, Roy O, Shepherd A, Bloom SL, McCartney SA. Henoch-Schönlein purpura complicating adalimumab therapy for Crohn’s disease. World J Gastrointest Pharmacol Ther 2010; 1(5): 119-122 [PMID: 21577306 DOI: 10.4292/wjgpt.v1.i5.119] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
570 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
571 Melgar S, Yeung MM, Bas A, Forsberg G, Suhr O, Oberg A, Hammarstrom S, Danielsson A, Hammarstrom ML. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol. 2003;134:127-137. [PMID: 12974765 DOI: 10.1046/j.1365-2249.2003.02268.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 104] [Article Influence: 5.4] [Reference Citation Analysis]
572 Uda A, Kuwabara H, Shimizu S, Iwakiri R, Fushimi K. Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease. JGH Open 2020;4:532-40. [PMID: 32514466 DOI: 10.1002/jgh3.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
573 Wan MX, Riaz AA, Schramm R, Wang Y, Vestweber D, Menger MD, Thorlacius H. Leukocyte rolling is exclusively mediated by P-selectinin colonic venules. Br J Pharmacol 2002;135:1749-56. [PMID: 11934816 DOI: 10.1038/sj.bjp.0704638] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
574 Lu J, Ding J, Liu Z, Chen T. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). Int J Oncol 2022;60:12. [PMID: 34981814 DOI: 10.3892/ijo.2022.5302] [Reference Citation Analysis]
575 Soriano CR, Powell CR, Chiorean MV, Simianu VV. Role of hospitalization for inflammatory bowel disease in the post-biologic era. World J Clin Cases 2021; 9(26): 7632-7642 [PMID: 34621815 DOI: 10.12998/wjcc.v9.i26.7632] [Reference Citation Analysis]
576 Bouguen G, Chevaux JB, Peyrin-Biroulet L. Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases. World J Gastroenterol 2011; 17(5): 547-556 [PMID: 21350703 DOI: 10.3748/wjg.v17.i5.547] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
577 de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13-27. [PMID: 26627550 DOI: 10.1038/nrgastro.2015.186] [Cited by in Crossref: 612] [Cited by in F6Publishing: 575] [Article Influence: 87.4] [Reference Citation Analysis]
578 Osterman MT, Lichtenstein GR. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007;10:195-207. [PMID: 17547858 DOI: 10.1007/s11938-007-0013-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
579 Shirota Y, Illei GG, Nikolov NP. Biologic treatments for systemic rheumatic diseases. Oral Dis 2008;14:206-16. [PMID: 18282173 DOI: 10.1111/j.1601-0825.2008.01440.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
580 Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798-805. [PMID: 17417731 DOI: 10.1007/s10620-006-9269-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
581 Castro Fernández M, García Díaz E, Romero M, Galán Jurado V, Rodríguez Alonso C. Tratamiento de la colitis ulcerosa corticorrefractaria con infliximab. Gastroenterología y Hepatología 2003;26:54-5. [DOI: 10.1016/s0210-5705(03)70344-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
582 Takedatsu H, Mitsuyama K, Torimura T. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11343-11352 [PMID: 26525603 DOI: 10.3748/wjg.v21.i40.11343] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]